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Decline in lung function is a risk factor for chronic obstructive pulmonary 
disease (COPD).  Vitamin D may protect against loss of lung function by 
modulating inflammation and tissue remodeling.  We investigated the 
association of serum 25-hydroxyvitamin D (25-OH-D) and genetic variants in 
vitamin D metabolic pathway genes with prognostic measures of obstructive 
lung disease including forced expiratory volume in the first second (FEV1) and 
the ratio of FEV1 to forced vital capacity (FEV1/FVC) using data from the 
Health Aging and Body Composition cohort study of adults aged 70-79.  We 
also obtained the first evidence of differential gene expression in lung 
epithelial cells associated with serum 25-hydroxyvitamin D in free-living 
humans. In regression models, there was a significant cross-sectional 
association of 25-OH-D with FEV1.  We detected no association between 25-
OH-D and rate of FEV1 decline over 10 years. The longitudinal results suggest 
that vitamin D supplementation in non-deficient individuals is unlikely to 
prevent decline in lung function in this age range.  However, results are also 
compatible with a beneficial effect of vitamin D earlier in life, which may 
 explain the cross-sectional association of 25-OH-D with lung function.  Single 
nucleotide polymorphisms (SNPs) in vitamin D metabolic pathway genes were 
tested in linear regression models stratified by race.  In African-Americans, 
rs3886163 and 2 haplotypes in CYP24A1 were associated with FEV1, and 
rs11168293 in VDR was associated with FEV1/FVC, after correction for 
multiple testing.  Two gene-environment interactions, between serum 25-OH-D 
and SNPs in RXRA, in European-Americans were significant with false 
discovery rate (FDR) < 0.2.  Microarray analysis was used to investigate gene 
expression in small airway epithelial cells associated with serum 25-OH-D in a 
separate study of 26 healthy, adult never-smokers.  Analysis was restricted to 
156 candidate genes with prior evidence of vitamin D-modulated gene 
expression in vitro and at least 1 predicted vitamin D response element. 
Thirteen genes had significant differences in expression, and 3 genes 
(KCNS3, FSTL1, and DAPK1) were significant with FDR < 0.2. Gene ontology 
and literature analysis of differentially expressed genes supported plausible 
mechanisms for functional roles in asthma, COPD, cancer, and response to 
infection in lung.  The physiological range of 25-OH-D is associated with 
functional differences in molecular outcomes in lung, implying mechanisms 
that explain and strengthen the plausibility of population-level studies showing 
associations of vitamin D with lung health.   
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CHAPTER 1 
INTRODUCTION TO VITAMIN D AND LUNG HEALTH 
 
Vitamin D Sources and Requirements 
 
Vitamin D is a prohormone that can be obtained either through diet/supplements or 
through biosynthesis in skin upon exposure to solar ultraviolet rays (UVB) [1,2].  
Ultraviolet rays from the sun can convert 7-dehydrocholesterol in skin into pre-vitamin 
D, which is subsequently converted into vitamin D [1]. Good dietary sources of vitamin 
D include fatty fish, supplements, and fortified foods such as milk and margarine [2].  
Recently, the Institute of Medicine (IOM) increased the Recommended Dietary 
Allowance (RDA) to 600 IU per day for adults and children age one and above 
(http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-
D.aspx). 
 
Vitamin D Metabolism 
 
Vitamin D from diet or produced through solar exposure is transported to the liver, 
where it is enzymatically converted by 25-hydroxylase (encoded by CYP2R1) into the 
major circulating form, 25-hydroxyvitamin D [3]. The largely unregulated hepatic 
conversion of both dietary and sunlight-derived vitamin D into 25-OH-D [4] makes 
serum 25-OH-D a good measure of vitamin D nutriture and the primary biomarker for 
vitamin D exposure [5]. Vitamin D is highly hydrophobic and requires the carrier 
molecule, Vitamin D binding protein (also known as DBP, encoded by GC), to circulate 
in the bloodstream.  25-hydroxyvitamin D is thus carried to the kidney, where it is 
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enzymatically converted to the more active form, 1,25-dihydroxyvitamin D, by 1-
hydroxylase (CYP27B1).  In addition to endocrine activity of kidney-derived 1,25-
dihydroxyvitamin D, evidence suggests a role for autocrine or paracrine 1,25-
dihydroxyvitamin D in regulation of immune function, cell growth, as well as many other 
functions [6,7].  This active metabolite is not used as a serum biomarker for vitamin D 
nutriture because it has a short half-life, is tightly regulated, and can be generated in 
localized tissues on demand [8].  Removal of the active form is accomplished when 
1,25-dihydroxyvitamin D is degraded by the 24-hydroxylase (CYP24A1) to form 1,24,25-
trihydroxyvitamin D. 
 
Vitamin D as a Steroid Hormone 
 
The cellular mechanism of action for vitamin D is through its ability to directly modulate 
gene expression, which has been clearly demonstrated in vitro [9,10]. Vitamin D 
influences gene expression through the binding of 1,25-OH2-D to the vitamin D receptor 
(VDR) in the cytoplasm of the target cell, as depicted in Figure 1.1.  The 1,25-OH2-
D:VDR complex, a heterodimer, enters the nucleus and can bind the retinoid X receptor 
(RXR).  The newly formed complex is able to recognize and bind target DNA sequences 
called vitamin D response elements (VDRE) [10,11]. VDR and RXR affect the ability of 
1,25-OH2-D to bind VDREs and thus have an important role in expression of VDRE 
containing genes [10,11].  VDREs are frequently located within the promoter regions of 
genes, and binding to a VDRE leads to regulation of transcription and thus regulation of 
the gene‘s protein product [9,12].  VDRE-containing genes are involved in a diverse 
array of physiological functions, including inflammation and immunomodulation 
[9,13,14]. 
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Figure 1.1. Vitamin D regulation of transcription through binding vitamin D responsive 
elements 
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Previous work in cell lines has led to the identification of genes directly up or down 
regulated by 1,25-OH2-D, and data mining has generated lists of genes with putative 
DR3 or ER6 hexameric VDRE sequences in their promoter regions [9].  
 
 
COPD 
 
 
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in 
the United States and has been diagnosed in more than 12 million Americans [15,16].  
The obstruction in the small airways of the lungs that characterizes COPD is typically 
diagnosed by using information from pulmonary function tests, which measure forced 
expiratory volume in the first second (FEV1) and maximum expiratory air volume when 
emptying the lungs (forced vital capacity, or FVC).  The Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) defines mild or stage 1 COPD according to the ratio 
of FEV1 to FVC (FEV1/FVC): a ratio less than 0.7 and an FEV1 ≥ 80% predicted (by age, 
race, gender, and height); similarly, other levels of COPD are defined by a ratio less 
than 0.7 and lower values for % predicted FEV1[17].  A steep decline in lung function is 
characteristic of COPD, and is also associated with increased risk of all-cause mortality 
in the elderly[18].  Pulmonary function decreases with age [19], although age-related 
decreases are typically not steep enough to lead to the loss of lung function that 
characterizes COPD.  Cigarette smoking is the single most important risk factor for 
steep declines in FEV1, however not all smokers develop COPD, and about 15% of 
COPD-related mortality arises in persons who have never smoked [20]. It is unclear why 
some non-smokers develop COPD and why some smokers never develop COPD.  
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There are likely additional environmental and/or genetic factors affecting the trajectory 
of lung function decline that have not yet been identified [21,22].  Mechanisms 
contributing to COPD in non-smokers and susceptibility factors in smokers are of great 
interest as they could suggest new targets for prevention efforts [19]. 
   
The inflammatory and tissue-remodeling processes of the cellular immune system can 
influence risk for obstructive lung disease.  These processes in the lung contribute to 
irreversible limitations of airflow [23].  Chronic inflammation within the small airways is a 
key characteristic of COPD pathology.  This inflammation occurs when exogenous 
substances enter the lung; in COPD sufferers, the most common exogenous exposure 
is cigarette smoke.  The effects of cigarette smoke have been demonstrated in animal 
models; for example, mice exposed to cigarette smoke for 24 weeks had an increased 
presence of inflammatory cells (neutrophils, macrophages, and lymphocytes) in small 
and large airways [24].  Dendritic cells have also been shown to infiltrate COPD 
airways, and their accumulation is proportional to disease severity [25].  Exposure to 
cigarette smoke activates dendritic cells and upregulates the expression of major 
histocompatibility complex II (MHC II) and co-stimulatory molecules, CD40 and CD86 
[24].  These effects on dendritic cells are part of the chronic inflammatory response to 
smoking that is observed in COPD [26].  Several studies suggest a relation between 
biomarkers of systemic inflammation and COPD, although results are not consistent.  A 
cross-sectional analysis in the Health, Aging, and Body Composition Study (Health 
ABC) found an inverse association between IL-6 and FEV1 in elderly participants with or 
without obstructive lung disease (regression coefficients: β = -5.3 and -3.1, respectively; 
p = .09) [27].  Patients with stable COPD had elevated serum levels of TNF-α and IL-6 
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[28], and a case control study of men with COPD reported a significant association of C-
reactive protein with COPD risk, but little or no association of either IL-6 or TNF-α [5,28].   
 
Tissue remodeling is understood to be another key factor in COPD pathology. The 
process of tissue remodeling affects the airways in COPD lungs through a combination 
of tissue destruction, reducing elasticity, and thickening of the walls of the small 
airways, which reduces airway diameter [29,30].  Thus, environmental or genetic factors 
producing individual differences in tissue remodeling capacity or efficiency is postulated 
to be related to disease risk. 
 
Vitamin D and lung health 
 
Although vitamin D is known primarily as a hormone responsible for regulation of serum 
calcium and phosphorous, preliminary evidence suggests a role for vitamin D in the 
occurrence and progression of COPD, as well as several other diseases affecting lung.  
Low serum 25-hydroxyvitamin D was associated with higher risk for severe 
exacerbation of mild-to-moderate persistent asthma in children [31], and a higher risk 
for active tuberculosis [32].  The possible role of vitamin D in lung cancer is 
controversial, but low serum 25-hydroxyvitamin D was a risk factor for lung cancer in 
women and young people [33], and high serum 25-hydroxyvitamin D was associated 
with improved survival in non-small cell lung cancer patients [34]. In contrast, cancer 
mortality was associated with both very low and very high vitamin D levels [35]. Vitamin 
D is associated with both asthma and COPD, but whether effects are causal is 
unknown, and mechanisms are not well understood [36].  
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Recent findings from the National Health and Nutrition Examination Survey show a 
direct association between serum 25-OH-D concentration and pulmonary function 
(FEV1 and FVC); these associations were strongest in the oldest age group studied (≥ 
60 years) [37].  However, a recent cross-sectional reported no association between 
serum 25-hydroxyvitamin D and lung function [38].  A prospective case-control study, 
comparing smokers with rapid rate of decline in FEV1 to smokers with shallow decline, 
reported no difference in plasma vitamin D at the beginning of the study period [39], but 
the analysis did not consider confounding and/or interactions with race, and the study 
did not include non-smokers.  Despite conflicting epidemiological evidence, studies in 
cell culture and animal models have shown that 1,25-dihydroxyvitamin D affects 
expression of genes related to inflammation, cell proliferation, and cell migration [40,41], 
which suggests plausible causal mechanisms for vitamin D associations with asthma, 
COPD, and lung cancer.  The limited epidemiologic data highlighted the need for further 
studies of these associations. 
 
Numerous studies connect vitamin D with modulation of chronic inflammation and 
airway remodeling [6,40,42,43,44,45].  For example, vitamin D inhibits the differentiation 
and maturation of dendritic cells, causing downregulation of MHC II, CD40, and CD86 
[41,46], suggesting a possible role for vitamin D in preventing or mitigating the 
responses of dendritic cells to chronic cigarette smoke exposure.  Other evidence 
suggests that vitamin D plays a role in suppression of inflammation through its effects 
on T helper 1 cells (Th1).  Increased Th1 levels have been found in the bronchoalveolar 
lavage of COPD patients [47].  Th1 cells contribute to the immune process primarily by 
increasing production of both CD8+ T cells and cytokines, including interferon-gamma 
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(IFN-) and tumor necrosis factor-alpha (TNF-) [48].  Vitamin D acts as an 
immunosupressive by impairing the production of key inflammatory Th1 cytokines. The 
active form of vitamin D, 1,25-dihydroxyvitamin D, inhibits secretion of the Th1 cytokines 
interleukin-2 (IL-2) and IFN- [49], and the serum biomarker, 25-hydroxyvitamin D, is 
associated with levels of these cytokines [49,50,51,52].  Additionally, 1,25-
dihydroxyvitamin D can inhibit myelocyte secretion of IL-12 [53], which is an essential 
cytokine in the differentiation of naïve T helper cells into Th1 cells [54].  Vitamin D is also 
associated with biological markers of systemic inflammation.  In the Baltimore Hip 
Studies (a cohort study of women ≥ 65 years of age with hip fractures in the previous 
year), study participants with vitamin D deficiency (serum 25-OH-D ≤ 15 ng/ml) had 
increased levels of IL-6 (p = 0.02), supporting the notion that vitamin D deficiency is 
proinflammatory [50].  Similarly, a study in healthy women (age 25 - 82 years) reported 
an inverse association between serum 25-OH-D and TNF-α (p = 0.0463) [51].  
 
The evidence that vitamin D plays a key role in tissue remodeling is mounting.  A recent 
study of gene expression in cultured bronchial smooth muscle cells found more than 
400 genes that were up or down-regulated in response to 1,25-dihydroxyvitamin D 
treatment; most of these genes were associated with cell proliferation and cell 
migration, hence likely to be important in the process of tissue remodeling and perhaps 
in carcinogenesis [40].  The matrix metalloproteases (MMPs) are involved in tissue 
remodeling in COPD [55].  Compared to healthy controls, patients with COPD have 
higher levels of sputum MMP-9 and a higher ratio of MMP-9 to its inhibitor, TIMP1 [56].  
Treatment of isolated bronchial smooth muscle cells with 1,25-dihydroxyvitamin D 
resulted in reduced expression of the metalloproteases MMP-9 and ADAM-33 [44].  
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Conversely, the metalloprotease inhibitors, TIMP-1 and TIMP-2, were found to be 
induced by 1,25-dihydroxyvitamin D in other cellular models [30,57].  Gene expression 
profiles of COPD lungs revealed increased expression of a protease, urokinase 
plasminogen activator (uPA), and its receptor, uPAR, both of which have been 
implicated in cell migration and extra-cellular matrix degradation [58].  Increased uPAR 
expression was associated with lower pulmonary function (FEF25-75%) [58].  In breast 
carcinoma cells, uPA expression was downregulated by 1,25-dihydroxyvitamin D in a 
dose-dependent manner [30].  Taken together, these findings are provocative, and point 
to a plausible biological mechanism linking vitamin D nutriture and COPD risk: this link, 
namely a role of vitamin D in tissue remodeling, has not been investigated directly to 
date.  Only one intervention study has reported the effect of vitamin D supplementation 
on inflammation and tissue remodeling biomarkers: in vitamin D deficient British 
Bangladeshi men, vitamin D supplementation (four intramuscular injections of 500 IU 
each over one year) decreased circulating serum levels of MMP-9 (68%) and CRP 
(23%) in relation to pre-supplementation values.  Vitamin D intervention was the only 
predictor of serum MMP-9 concentrations [59].  
 
Interestingly, preliminary evidence suggests that SNPs in the gene encoding the vitamin 
D binding protein, or GC, are associated with COPD risk.  A study comparing the 
relative risk for COPD associated with the three most common GC alleles, GC1F, 
GC1S, and GC2 (alleles each having different non-synonomous polymorphisms) 
suggested a protective effect for the homozygous GC2 genotype (OR = 0.17, 95% CI = 
0.03 to 0.83) [60].  Similar results were observed in previous studies: the homozygous 
GC2 genotype was protective, with relative risks of 0.2 and 0.7 for COPD [61,62].  A 
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separate study in 88 healthy, Japanese smokers identified homozygous GC1F as an 
increased COPD risk genotype (OR = 2.3; 95% CI = 1.2 to 4.6) [63].  A study comparing 
COPD smokers with asymptomatic smokers in Han Chinese found a higher proportion 
of the GC1F allele in COPD smokers, with an odds ratio of 3.5 for the homozygous 
GC1F genotype.  This study also found a higher proportion of the GC2 allele in 
asymptomatic smokers than in COPD smokers [64].  A proposed mechanism for the 
functional effects of the GC alleles stems from their effect on vitamin D binding affinities: 
differences are reported among the three common GC alleles.  Of the three common 
alleles, GC1F had the lowest affinity for vitamin D, with a Ka of 1.12 ± 0.13 nM and 1.80 
± 0.21 nM for 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, respectively.  The 
GC1S Ka was 0.60 ± 0.15 nM and 0.64 ± 0.10 nM for 25-hydroxyvitamin D and 1,25-
dihydroxyvitamin D, respectively.  The GC2 genotype had the highest affinity for vitamin 
D, with a Ka of 0.36 ± 0.10 nM and 0.42 ± 0.11 nM for 25-hydroxyvitamin D and 1,25-
dihydroxyvitamin D, respectively [65].  A difference in binding affinity could produce a 
difference in concentration of vitamin D reaching cells; measures of gene expression at 
the target cell would reveal this relationship, but no published research has studied this 
directly. Polymorphisms in VDR are also associated with lung phenotypes, including 
sarcoidosis [66], asthma [67,68], pulmonary tuberculosis [69], and non-small cell lung 
cancer [34]. If the associations with vitamin D are causal, the public health implications 
are significant because the consequences of vitamin D insufficiency are amenable to a 
simple intervention. 
 
Factors Affecting Vitamin D Status 
 
Genetics may also affect levels of circulating vitamin D; the SUNLIGHT consortium 
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reported significant contribution of transport and metabolism genes to serum 25-
hydroxyvitamin D concentrations [9], and high heritability of serum vitamin D 
concentrations [70].  Skin color also affects vitamin D levels because skin pigmentation 
interferes with vitamin D synthesis in response to sunlight [5].  An estimated 32% of 
African Americans are deficient (<12 ng/mL serum 25-hydroxyvitamin D) in vitamin D 
[71].  Aging Americans are also more likely to have insufficient levels of serum 25-
hydroxyvitamin D, in addition to being at risk of lower pulmonary function [72,73]. The 
prevalence of vitamin D deficiency has been shown to increase with age [72]; the 
elderly (> 65 years of age) are most at risk for vitamin D deficiency due to a combination 
of biological and lifestyle factors, including reduced production of vitamin D in skin, 
reduced outdoor activity, and fewer sources of vitamin D in the diet [73].  Because 
inadequate vitamin D levels are common and frequently overlooked in preventive 
medical care [74], this modifiable environmental factor could affect a large proportion of 
the at-risk population for COPD and other lung disorders.   
 
Unresolved Issues in the Field 
 
Observational studies of vitamin D share an important limitation in that status of this 
nutrient is often correlated with general health; moreover, because illness may lead to 
reduced outdoor activity and sun exposure, reverse causation may be at play in cross-
sectional studies.  In addition, association studies of vitamin D typically rely on a single 
measurement of serum 25-hydroxyvitamin D, which may not be an accurate proxy for 
an individual‘s average status over a lifetime, from the prenatal period through 
adulthood.  Attempts to adjust statistically for seasonal variation of serum 25-
hydroxyvitamin D levels are also imperfect.  
 12 
 
 
The recent IOM specification of the RDA for vitamin D disappointed some critics who 
claimed that requirements were not high enough; controversy remains because some 
researchers in the field maintain that at least 75 nM 25-hydroxyvitamin D (30 ng/mL) 
should be the cut-point for adequacy, whereas the IOM recommendations are based on 
dietary amount needed to attain 50 nM (20 ng/mL) serum 25-hydroxyvitamin D [75].  
The IOM panel used only bone health to develop the dietary reference intakes; 
evidence for other outcomes, such as cancer, respiratory infections, and asthma, was 
rejected based on dubious causality (as described above for observational studies), 
contradictory results (as described above for cancer), or insufficient data to establish a 
dose-response relationship [75].  The latter problem is especially relevant to lung 
outcomes, in which the majority of evidence is based on effects of 1,25-
dihydroxyvitamin D, without any known correspondence of these doses to levels of the 
biomarker, 25-hydroxyvitamin D.  Thus, studies designed to bridge the gap between 
effects of 1,25-dihydroxyvitamin D in vitro and associations of 25-hydroxyvitamin D in 
vivo are especially needed. 
 
Summary of Research Approach 
 
The studies described in this dissertation seek to create a connection between in vitro 
and animal model experimentation and observational evidence in humans.  Although 
our work is observational in nature, the studies were designed to strengthen causal 
inferences, and to demonstrate mechanisms of vitamin D action in free-living humans.   
A conceptual framework of the hypothesized mechanisms for the associations being 
studied in this dissertation is depicted in Figure 1.2. 
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Figure 1.2. Hypothesized mechanism of action for vitamin D and vitamin D metabolic 
SNPs in lung health. 
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The first study investigates the hypothesis that higher serum 25-OH-D is associated 
with attenuation in the rate of decline in FEV1 using data available from the Health, 
Aging and Body Composition Study (Health ABC).  Health ABC is a prospective study of 
3,075 healthy (free from disability and functional limitation in daily living) people aged 70 
to 79 at baseline focused on changes in body composition and decline in function in 
healthy, older persons.  The study has approximately as many male as female 
participants, with African Americans representing 33% of male and 46% of female 
participants.  By examining both cross-sectional and longitudinal relationships, we aim 
to provide evidence less susceptible to reverse causality than previous epidemiologic 
studies of vitamin D and lung function. 
 
The second study investigates the association of genetic variation in vitamin D 
metabolic pathway genes with lung function (FEV1 and FEV1/FVC) using data from the 
Health ABC 1 Million marker genome-wide association study.  We examine all genes 
that function in the pathway, from 25-hydroxyvitamin D synthesis to degradation of 1,25-
dihydroxyvitamin D.  Relationships of individual single nucleotide polymorphisms 
(SNPs), haplotypes, and gene-environment interactions of serum 25-hydroxyvitamin D 
level and genotype are examined.  Genetic evidence represents the cumulative effect of 
a lifetime of altered vitamin D functionality; as such, it is free from the lifestyle 
confounding and measurement issues that may be problematic in association studies 
based on 25-hydroxyvitamin D concentration.  Positive associations found in this study 
will greatly support a role for vitamin D in lung function. 
 
The third study investigates the hypothesis that low/inadequate serum 25-OH-D is 
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associated with significant changes in gene expression in small airway lung epithelial 
cells, and that these changes occur in genes from functional categories potentially 
relevant to pathogenesis of COPD and other lung diseases. This study reveals 
underlying mechanisms for vitamin D effects in lung, and establishes a relationship 
between function at the molecular level and circulating concentration of 25-
hydroxyvitamin D in free-living humans. 
 
 
 
Conclusion 
Preliminary evidence for a possible role for vitamin D in maintaining lung health has 
already engendered a call for a vitamin D intervention study in COPD [76].  However, 
even if the conflicting epidemiological evidence is to be disregarded, not enough data 
exists to determine optimal vitamin D levels or dosing, or the appropriate age group to 
receive such an intervention.  Moreover, the mechanisms underlying an effect of vitamin 
D in lung tissue have not been fully elucidated.  
 
The studies presented here attempt to replicate cross-sectional findings of an 
association of vitamin D with lung function, and extend those findings to longitudinal 
effects in an elderly population.  These results may aid in determination of optimal age 
ranges for preventive intervention strategies.  We also investigate the role of vitamin D 
in lung health more directly, through a study of SNPs in genes that control vitamin D 
metabolism.  Understanding gene regulation by vitamin D in lung epithelium could also 
provide further evidence for functional mechanisms of protection against COPD, which 
must be better understood if improved treatments are to be found. 
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No studies to date have examined whether genes regulated by vitamin D in cell models 
are similarly regulated in free-living humans.  In view of the current controversy over 
recommendations for optimal serum 25-hydroxyvitamin D [77], a method to assess 
dose-dependent function via gene expression is important to the broader field of vitamin 
D research and public health. Furthermore, characterization of changes in gene 
expression associated with low serum 25-hydroxyvitamin D will help to demonstrate that 
differences in serum 25-hydroxyvitamin D are associated with meaningful physiological 
changes in gene regulation. These studies have the potential to identify genetic markers 
and new drug targets related to lung function decline and COPD risk, and to inform 
preventive medicine and clinical care by providing evidence relevant to lifestyle 
interventions to optimize vitamin D levels, which may be important in extending the 
healthy lifespan. 
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CHAPTER 2 
ASSOCIATION OF SERUM VITAMIN D WITH LUNG FUNCTION IN THE HEALTH, 
AGING AND BODY COMPOSITION (HEALTH ABC) STUDY 
 
 
Abstract 
Decline in lung function is a risk factor for chronic obstructive pulmonary disease 
(COPD).  Vitamin D may protect against loss of lung function through modulation of 
inflammation and tissue remodeling processes.  We investigated the cross-sectional 
and longitudinal association of serum 25-hydroxyvitamin D (25-OH-D) with prognostic 
measures of obstructive lung disease, FEV1 and FEV1/FVC.  Analysis was conducted in 
the Health ABC study of well-functioning adults aged 70-79.  The association of 25-OH-
D and FEV1 and FEV1/FVC was estimated in regression models, which were adjusted 
for age, sex, height, race, smoking, season, and study site.  The cross-sectional 
association of 25-OH-D with FEV1 was statistically significant, positive, and non-linear 
(p<0.0001 and p=0.0012 for linear and quadratic model terms, respectively).  
Participants with 10 ng/mL serum 25-OH-D (in the range defined as deficient) had a 
mean baseline FEV1 132 mL lower than participants with 30 ng/mL 25-OH-D (in the 
range defined as adequate).  In the initial longitudinal analysis, higher serum 25-OH-D 
was associated with a steeper FEV1 decline.  However, further inspection showed that 
the shallower rate of FEV1 decline in participants with low 25-OH-D was due to 
increased missed clinic visits and subsequent selective loss of FEV1 measurements in 
these participants over 10 years of follow-up.  When analyses were limited to the upper 
2 tertiles of serum 25-OH-D (20.6 ng/mL - 75 ng/mL), there was no association between 
25-OH-D and rate of FEV1 decline. The longitudinal results suggest that vitamin D 
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supplementation in non-deficient individuals is unlikely to prevent decline in lung 
function in this age range.  However, results are also compatible with a beneficial effect 
of vitamin D earlier in life, which may explain the cross-sectional association of 25-OH-D 
with lung function.   
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Introduction 
A steep decline in lung function is the hallmark of chronic obstructive pulmonary disease 
(COPD), and also a predictor of an increased risk of all-cause mortality in the elderly[1]. 
 COPD is the third leading cause of death in the United States, and an understanding of 
mechanisms contributing to decline in lung function is a critical public health 
concern[2,3].  While cigarette smoking is the single most important risk factor for a 
steeper rate of decline in lung function and the primary risk factor for COPD, about 15% 
of COPD arises in persons who have never smoked, and not all smokers are 
susceptible [4].  Factors contributing to COPD in non-smokers and susceptibility factors 
in smokers are of great interest as they could suggest new targets for prevention efforts 
[5].  Age-related decreases in pulmonary function are typically not steep enough to lead 
to the loss of lung function that characterizes COPD.  Thus, aside from smoking, other 
environmental and/or genetic factors are hypothesized to affect the trajectory of lung 
function decline[6,7].  Currently available drugs treat symptoms, but do not cure COPD; 
thus, research to identify factors associated with lung function decline may yield clues 
for future drug development and/or lifestyle interventions to prevent disease and/or to 
slow disease progression.   
 
The obstruction in the small airways of the lungs that characterizes COPD is diagnosed 
by pulmonary function testing, and more specifically by the forced expiratory volume in 
the first second (FEV1) and the forced vital capacity (FVC).  The Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) defines mild or stage 1 COPD as an 
FEV1/FVC ratio < 0.7 and an FEV1 ≥ 80% predicted (by age, race, gender, and 
height)[8].  Given the hypothesis studied here focuses on obstructive lung disease, the 
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FEV1 and FEV1/FVC ratio were the main outcomes investigated.  
 
Prior research supports a role for vitamin D, as measured by its main circulating form, 
serum 25-hydroxyvitamin D, in lung health.  In adults in the Third National Health and 
Nutrition Examination Survey (NHANES III) serum 25-hydroxyvitamin D concentration 
was positively associated with pulmonary function parameters (FEV1 and FVC), and the 
association was strongest in the oldest age group[9].   In addition to being at risk of 
morbidity associated with declining pulmonary function, elderly Americans are more 
likely to have low serum 25-hydroxyvitamin D[10,11].  Vitamin D is a sunlight-derived 
hormone that is primarily known for its role in regulating serum calcium and 
phosphorous, but the association of vitamin D with lung function is hypothesized to 
reflect a mechanism involving chronic inflammation and airway 
remodeling[12,13,14,15,16,17].  The hypothesized role of vitamin D as an 
immunomodulator and as a factor in tissue remodeling suggests plausible biological 
mechanisms for a causal role of vitamin D in promoting and maintaining lung health 
over the life course, but the epidemiological data supporting this association remain 
limited.   
 
To date, the only epidemiologic evidence supporting a role for vitamin D in lung function 
is cross-sectional[9].  This result has been contradicted by a second cross-sectional 
study that reported no association between serum 25-hydroxyvitamin D and lung 
function[18].  A recent case-control study, comparing smokers with rapid rate of decline 
in FEV1 to smokers with shallow decline, reported no difference in plasma vitamin D at 
the beginning of the study period[19], but the analysis did not consider confounding 
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and/or interactions with race, and the study did not include non-smokers.  Prospective 
studies of diverse populations, including older adults, smokers and non-smokers, and 
different races, are needed to more fully investigate the role of vitamin D status in lung 
function decline and pulmonary health.    
 
This study investigates the hypothesis that serum 25-hydroxyvitamin D is inversely 
associated with the rate of decline in FEV1 and FEV1/FVC. Participants in the Health, 
Aging, and Body Composition prospective cohort study (Health ABC) were studied, and 
both cross-sectional and longitudinal associations of serum vitamin D and pulmonary 
function were investigated.    
 
 
Materials and Methods 
 
Study Population 
The Health ABC study, a longitudinal cohort study, tracks a period of rapid health 
transitions in the elderly.  A random sample of Whites and all Black Medicare-eligible 
persons residing in ZIP codes from the metropolitan areas surrounding Pittsburgh, PA 
and Memphis, TN were invited to join the study, and the final study comprised 3,075 
Black  and White men and women (46% of women and 37% of men were Black).  
Eligibility criteria included: aged 70 to 79 in the recruitment period (March 1997 to July 
1998); self-report of no difficulty walking one-quarter of a mile or climbing 10 steps 
without resting; no difficulty performing basic activities of daily living; no reported use of 
a cane, walker, crutches or other special equipment to ambulate; no history of active 
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treatment for cancer in the prior 3 years; and no plan to move out of the area in the 
subsequent 3 years.  Further details of this population are described elsewhere 
(http://www.nia.nih.gov/ResearchInformation/ScientificResources/HealthABCDescription
.htm). 
 
Participants were excluded from this analysis if they were missing measurements or 
had extreme outlier serum 25-hydroxyvitamin D (>100 ng/mL).   Individuals with 
prevalent COPD were excluded from these analyses given further changes in their lung 
function are affected by treatment and/or the disease process itself. Prevalent COPD 
was defined by spirometry values, according to the GOLD-criteria, but modified to use 
the lower limit of normal (LLN) given age-associated loss in pulmonary function leads to 
over-diagnosis with the use of definitions based on ratio < 0.70. Thus, participants with 
an FEV1/FVC below the lower limit of normal (LLN, defined as the 5
th percentile in 
people of similar age) were excluded.  Other exclusion criteria were self-reported 
physician-diagnosed asthma at baseline, missing smoking history, or no FEV1 and 
FEV1/FVC measurements with acceptable quality scores. 
 
Spirometry and Vitamin D Measurements 
FEV1 and FVC were measured using NIOSH spirometry systems at year 1, 5, 8, and 10 
follow-up visits (corresponding to 0, 4, 7 and 9 years on study).  Measurement quality 
was assessed using American Thoracic Society standardization of spirometry 
guidelines[20,21].  Acceptable quality was defined as having no early coughs, no early 
termination, limited extrapolated volume, and ≤ 200 ml between the two best FEV1 
measurements at each visit (based on criteria in use at the time of this study).  Serum 
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25-hydroxyvitamin D was assessed in stored serum from the year 2 visit using the 
Diasorin RIA assay according to manufacturer specifications (November 2006).  The 
inter-assay coefficient of variation for the measurement of 25-hydroxyvitamin D was 
6.78% for log-transformed values[22]. 
 
Statistical Analysis 
The cross-sectional association of 25-hydroxyvitamin D with FEV1 or FEV1/FVC was 
examined using ordinary least squares regression.  Age, gender, height, race, current 
smoking status, Health ABC study site, and season of blood collection were included as 
covariates in the models, and the non-linearity of the vitamin D—pulmonary function 
association was considered.  The interaction of vitamin D with smoking status, race, and 
comorbidities (hypertension, cardiovascular disease, all cancers except skin cancer, 
diabetes) were evaluated by adding product terms to the model.   
 
Longitudinal analysis used linear mixed models to estimate the association of serum 25-
hydroxyvitamin D with decline in FEV1 or FEV1/FVC.  Age, gender, height, race, current 
smoking status, smoking pack years, Health ABC study site, and season of blood 
collection were included as covariates in the models, and race and comorbidities were 
evaluated as effect modifiers of the serum vitamin D—pulmonary function association. 
 To determine the associations of 25-hydroxyvitamin D with rate of decline in FEV1 or 
FEV1/FVC, models included a time variable that quantified time elapsed from study 
entry to each spirometry measurement; interaction terms between 25-hydroxyvitamin D 
and the time variable were evaluated to quantify the association of vitamin D with rate of 
decline.  Outlier points for FEV1 were excluded if the absolute value of conditional 
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Studentized residual was > 5.   Follow-up analysis to detect selection bias included 
evaluation of percent mortality and missed clinic visits in each tertile of 25-
hydroxyvitamin D level.  All analyses were carried out in SAS version 9.1 (Cary, NC). 
 
Results 
Population Characteristics 
A total of 2,015 participants from the Health ABC cohort were included to investigate the 
cross-sectional associations of FEV1 and FEV1/FVC ratio with serum 25-hydroxyvitamin 
D.   Participants with low quality control scores on spirometry, missing smoking status 
and/or history, missing year 2 serum 25-hydroxvitamin D, report of prevalent doctor-
diagnosed asthma, or prevalent spirometry-defined COPD (defined as an FEV1/FVC 
ratio below LLN) were excluded from further analyses.  Thus, the longitudinal analysis 
included 1,983 participants (Table 2.1).  Participants included in the longitudinal 
analysis met the same inclusion criteria as in the cross-sectional analysis, but also were 
required to have data on lifetime, cumulative smoking (pack years).  The characteristics 
of participants at the study baseline were compared between included and excluded 
participants.  Both the cross-sectional and the longitudinal study populations were 
similar, thus only the cross-sectional comparisons are shown.  Excluded participants 
had a higher proportion of Black participants, higher average smoking pack-years, and 
lower average FEV1 at study baseline.  Black participants were more likely to be 
excluded from analyses due to a higher frequency of low spirometry quality control 
scores; 9.1% of Blacks and 3.1% of Whites were excluded for low quality control scores 
on spirometry.  Additionally, participants excluded due to prevalent COPD and/or 
asthma had higher smoking pack years and lower FEV1 at the study baseline, thus 
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included participants generally had higher FEV1 and lower smoking pack-years.   
 
The cross-sectional association of serum 25-hydroxyvitamin D with lung function was 
estimated in regression models, which were adjusted for age, sex, height, race, 
smoking, season of blood collection, and study site.  Physical performance, alcohol 
consumption, education, and BMI were considered as possible confounders, but were 
not included as covariates in the models because inclusion had no effect on the 
coefficient for 25-hydroxyvitamin D, or the variable was potentially causally antecedent 
to 25-hydroxyvitamin D levels.  The association between serum 25-hydroxyvitamin D 
and FEV1 was positive and non-linear (Figure 2.1); regression coefficients for the linear 
and quadratic terms for serum 25-hydroxyvitamin D were 14.75 (p < 0.0001) and -0.20 
(p = 0.0012), respectively.  To interpret the coefficients, predicted values for the FEV1 at 
different serum vitamin D concentrations were computed based on the model; the 
average FEV1 in vitamin D-deficient participants (serum 25-hydroxyvitamin D of 10 
ng/mL) was 132 mL lower than the average in participants with 30 ng/mL serum 25-
hydroxyvitamin D (note: the 30ng/mL concentration is within the range defined as safe 
and adequate by the Office of Dietary Supplements and the Institute of Medicine; 
http://ods.od.nih.gov/factsheets/vitamind/, http://www.iom.edu/Reports/2010/Dietary-
Reference-Intakes-for-Calcium-and-Vitamin-D.aspx).  While the mean serum 25-
hydroxyvitamin D differed by race (20.78 ng/mL and 28.97 ng/mL for Black and White 
participants, respectively), there was no evidence for an interaction of race and serum 
25-hydroxyvitamin D in models predicting FEV1 (p = 0.93 and 0.94 for the interaction 
coefficients). Further models assessed the interaction of serum 25-hydroxyvitamin D 
with smoking status (p = 0.95 and 0.99), gender (p = 0.39 and 0.75), and comorbidities, 
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but no interactions terms were statistically significant.  There was little or no association 
between serum 25-hydroxyvitamin D and the ratio of FEV1/FVC ratio (regression 
coefficient = -0.003 SE = .013; p = 0.7961).    
 
The association of serum 25-hydroxyvitamin D with rate of decline in FEV1 was 
estimated in mixed models adjusted for age, sex, height, race, smoking, season of 
blood collection, and study site.  Higher serum 25-hydroxyvitamin D was associated 
with a steeper rate of FEV1 decline; thus for every unit increase in serum 25-
hydroxyvitamin D the rate of decline increased by 0.30 mL/year (p < 0.0001). 
Comparing participants who were deficient (10ng/mL) to participants in the adequate 
range for 25-hydroxyvitamin D (30ng/mL), the adequate group had an average rate of 
decline that was 6mL/year less steep than the rate in the deficient group.  No significant 
longitudinal interactions between serum 25-hydroxyvitamin D and race or comorbidities 
were observed.  There was little or no association of serum 25-hydroxyvitamin D with 
the trajectory of change in the ratio of FEV1/FVC ratio (p = 0.2241).   
 
The positive association between serum 25-hydroxvitamin D and rate of decline in lung 
function was unexpected.  A possible explanation for this finding is selection bias if 
participants with lower serum 25-hydroxvitamin D experienced increased morbidity and 
mortality that led to incomplete pulmonary function testing for the longitudinal analysis. 
To investigate whether selection bias affected the rate of FEV1 decline at lower levels of 
serum 25-hydroxvitamin D, morbidity (clinic attendance) and mortality patterns were 
examined by tertile of serum 25-hydroxvitamin D (baseline characteristics of tertiles are 
presented in Supplemental Table 2.1).   Participants in the lowest tertile of serum 25-
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hydroxvitamin D had lower FEV1 at study baseline compared to participants in the upper 
two tertiles (Supplemental Table 2.2).  Participants in the lowest tertile of serum 25-
hydroxvitamin D were also more likely to die or miss clinic visits over the study follow-up 
period (Figures 2.2a and 2.2b).  Compared to the highest tertile of serum 25-
hydroxyvitamin D, participants in the lowest tertile were more likely to have only a 
baseline FEV1 measurement and less likely to have all four FEV1 measurements from 
baseline and years 5, 8, and 10 (Supplemental Table 2.3).  As a result, longitudinal 
pulmonary function data were less likely to be available on participants with the lowest 
serum 25-hydroxvitamin D, due to missing year 5, 8, and/or 10 pulmonary function 
measurements.  The selective loss of data from participants at lower 25-hydroxyvitamin 
D levels may result in overall better trajectories in FEV1 among the remaining 
participants with lower 25-hydroxyvitamin D levels creating a non-representative group 
with repeated measurements of pulmonary function.  This selection bias may explain 
the observation that participants with lower serum 25-hydroxvitamin D had a shallower 
rate of decline in FEV1.    
 
To address selection bias, a sensitivity analysis assessed the association of serum 25-
hydroxvitamin D with rate of decline in FEV1 in an analysis limited to participants in the 
top two tertiles of serum 25-hydroxvitamin D (a range that is not associated with vitamin 
D deficiency and/or insufficiency).  Of note, the serum concentration of 25-
hydroxvitamin D currently under scrutiny for determination of optimal levels is included 
in the highest two tertiles of 25-hydroxvitamin D (20.6 - 74.7 ng/mL) in the study 
population.  In this analysis, there was little or no association of  serum 25-
hydroxvitamin D with rate of decline in FEV1 (Table 2.2, regression coefficient = -0.12 
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mL/year; SE = 0.12; p = 0.28).  Similarly, there was little or no cross-sectional 
association of serum 25-hydroxvitamin D with FEV1 when analysis was limited to the 
two highest tertiles of 25-hydroxvitamin D. 
 
Discussion 
Serum 25-hydroxyvitamin D is positively associated with FEV1 in the cross-sectional 
analysis, but not with the FEV1/FVC ratio in elderly participants of the Health, Aging, 
and Body Composition study.  This finding is consistent with a prior report from 
NHANES III, which showed that serum 25-hydroxyvitamin D was positively associated 
with FEV1, but not with FEV1/FVC ratio [9]. The findings contradict a recent finding from 
the U.K.-based Hertfordshire Cohort Study[18]. Of great interest, in a longitudinal 
analyses of Health ABC follow-up data there was no evidence for an association of 
serum 25-hydroxyvitamin D with the trajectory of decline in the FEV1/FVC ratio. 
 Although a positive association between serum 25-hydroxyvitamin D and rate of 
decline in FEV1 (higher serum vitamin D associated with steeper rate of decline) was 
observed, further analysis suggests this result is due to selection bias. Thus, 
participants in the lowest tertile of 25-hydroxyvitamin D experienced both higher 
mortality and more missed clinic visits, leading to an under-representation of 
participants with lower serum vitamin D status in the longitudinal study. When analyses 
were limited to the uppermost tertiles of serum 25-hydroxyvitamin D, where far fewer 
participants were lost to follow-up, there was little or no association of serum 25-
hydroxyvitamin D measured early in follow-up (range 20.6 to 74.7 ng/mL) with the 
subsequent rate of decline in FEV1.   
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The use of the Health ABC cohort may have introduced several limitations, including the 
selection bias described above arising because missing longitudinal lung function 
measurements occurred disproportionately in participants with low 25-hydroxyvitamin D 
levels. In addition, serum 25-hydroxyvitamin D was measured in the second year of the 
study, while the first measurement of pulmonary function was in year 1.  This introduces 
the possibility that poor health associated with lower lung function could have led to 
lower 25-hydroxyvitamin D status the following year due to reduced sunlight exposure 
from reduced outdoor activity.  As with all cross-sectional associations of 25-
hydroxyvitamin D, there is the possibility that serum 25-hydroxyvitamin D is a proxy for 
overall health rather than a causal contributor to lung function.    
 
Ideally, longitudinal studies help resolve temporal sequence and reverse causality 
concerns.  Kunisaki et al[19] recently reported a study of 196 smokers with 6 years of 
follow-up, comparing mean serum 25-hydroxyvitamin D in steep FEV1 decliners (cases) 
with shallow FEV1 decliners (controls); no analyses of baseline cross-sectional 
associations were presented, statistical models were not adjusted for race despite a 
significant difference in race between cases and controls, and serum vitamin D was 
measured late in follow-up (one year before the study ended).  There was little or no 
difference in serum 25-hydroxyvitamin D between steep and shallow FEV1 decliners, 
but the limitations of the study preclude definitive conclusions and provide no 
information about non-smokers.    
 
The Health ABC study reported herein is the first longitudinal analysis of serum 25-
hydroxyvitamin D in relation to rate of decline in FEV1 and the FEV1/FVC ratio in a large 
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and racially diverse population that includes a large proportion of healthy non-smokers. 
  Our cross-sectional analysis support the positive association between serum 25-
hydroxyvitamin D and FEV1 reported by Black, et al.[9], but contradict the recent report 
by Shaheen, et al.[18].  The longitudinal analysis of decline in FEV1 and decline in the 
FEV1/FVC ratio over 10 years revealed little or no association of serum 25-
hydroxyvitamin D with rate of decline, suggesting that supplementing vitamin D in older 
adults with serum values of 20 ng/mL or higher is unlikely to be beneficial. 
 
Although we had to eliminate the most severely vitamin D deficient participants from the 
longitudinal analysis, the range of vitamin D nutriture studied represents the range that 
is most hotly debated in the current controversy over defining sufficient and/or optimal 
25-hydroxyvitamin D levels.  Although there is no doubt that it is beneficial to 
supplement vitamin D deficient (< 12 ng/mL according to the Office of Dietary 
Supplements, http://ods.od.nih.gov/factsheets/vitamind/) patients for reasons that go 
beyond lung health, the Institute of Medicine has defined current dietary 
recommendations based on intake required to achieve 20 ng/mL serum 25-
hydroxyvitamin D in 97.5% of the population (http://ods.od.nih.gov/factsheets/vitamind/, 
http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-
D.aspx).  Our study suggests further supplementation in older patients with serum 25-
hydroxyvitamin D above approximately 20 ng/mL will not mitigate lung function decline. 
However, results from on-going trials of vitamin D supplementation will provide 
important further evidence. 
 
Including the study reported herein, 2 studies confirm a cross-sectional association of 
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25-hydroxyvitamin D status and FEV1, and 2 studies confirm no association of 25-
hydroxyvitamin D with longitudinal FEV1 decline.  As mentioned above, a potential 
explanation is that the cross-sectional result reflects overall health of the participants 
and not a casual association.  Another possibility, however, is that vitamin D has a 
causal role in attenuating FEV1 decline at an earlier stage in life than the age range 
investigated in studies to date.  This is consistent with a cross-sectional difference in 
FEV1 by vitamin D status observed in older Americans.  A causal role for vitamin D is 
supported by vitamin D‘s known role in important lung function processes such as 
inflammation and tissue remodeling, and cannot be ruled out based on the findings from 
the Health ABC study.   
 
These issues highlight the need for longitudinal studies in a younger age group, which 
would also avoid the issues arising from morbidity/mortality-related selection bias.  Our 
results suggest the possibility that an intervention of vitamin D supplementation to 
improve lung health may only be effective at younger ages, or only in people with true 
vitamin D deficiency.  These results demonstrate the need for further studies to evaluate 
whether a longitudinal association exists, and to define the optimal timing for 
intervention. 
 
Tremendous enthusiasm for vitamin D supplementation for lung function has been 
generated by a single cross-sectional result, which we have replicated here.   The study 
reported herein presents the first longitudinal results examining the association of 25-
hydroxyvitamin D with decline in FEV1 and FEV1/FVC ratio in a large cohort comprised 
of both smoking and non-smoking older adults.  Participants with serum 25-
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hydroxyvitamin D below approximately 20 ng/mL at year 2 had higher rates of missed 
clinic visits and mortality in subsequent years, suggesting that this level of vitamin D 
may be a prognostic indicator for overall poor health in later years.  However, in 
participants in this age group, there was no evidence that vitamin D supplementation 
would attenuate decline in lung function. 
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Table 2.1.  Baseline Characteristics of Health ABC Participants Included* and Excluded 
from Analyses 
 
  
Cross-
sectional* 
Cross-sectional 
Excluded Longitudinal* 
Longitudinal 
Excluded 
  
  (n =2015 ) (n = 1060) (n = 1979) (n = 1096) 
  
 Age, years (SD)  73.6 (2.9) 73.7 (2.9) 73.6 (2.9) 73.7 (2.9) 
  
 Females (%) 1024 (51%) 467 (44%) 1002 (51%) 489 (45%) 
  
 Blacks (%) 728 (36%) 553 (52%) 720 (36%) 561 (51%) 
  
 Memphis, TN site (%) 1036 (51%) 491 (46%) 1022 (52%) 505 (46%) 
  
 Former Smokers (%) 930 (46%) 474 (45%) 902 (46%) 502 (46%) 
  
 Current Smokers (%) 169 (8.4%) 149 (14%) 166 (8.4%) 152 (14%) 
  
 Packyears (SD) 17.4 (26.5) 22.1 (30.4) 17.5 (26.6) 22.0 (30.0) 
  
 Height, cm (SD)  166.7 (9.2) 165.3 (9.6) 166.4 (9.1) 165.4 (9.7) 
  
 BMI, kg/m2 (SD)  27.4 (4.6) 27.5 (5.2) 27.4 (4.6) 27.5 (5.2) 
  
FEV1 at baseline, mL (SD)  2284 (608) 1819 (615) 2282 (609) 1844 (625) 
  
FEV1 ratio at baseline 
(SD)  75.71 (5.73) 73.77 (13.6) 75.72 (5.72) 73.83 (13.3) 
 
 
 Serum 25-hydroxyvitamin, 
ng/mL (SD)  
26.0 (10.1) 
 
25.3 (14.2) 
 
26.0 (10.1) 
 
24.5 (14.0) 
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Figure 2.1. Non-linear association of year 2 serum 25-hydroxyvitamin-D with baseline FEV1  
(Dashed line represents the 95% confidence interval)  
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Figure 2.2a.  Mortality by tertile of serum 25-hydroxyvitamin D* through 10 years of follow-up.   
*Tertile 1: 5.01 – 20.57 ng/mL, Tertile 2: 20.58 – 29.87 ng/mL, Tertile 3: 29.88 – 74.74 ng/mL
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Figure 2.2b.  Missed clinic visits by tertile of serum 25-hydroxyvitamin D* through 10 years of follow-up.   
Missed clinic visits include missed visits for any reason, including mortality.   
*Tertile 1: 5.01 – 20.57 ng/mL,Tertile 2: 20.58 – 29.87 ng/mL, Tertile 3: 29.88 – 74.74 ng/mL
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Table 2.2.  Change in FEV1 Decline by Tertile of Serum 25-hydroxyvitamin D* Over 10 
Years of Follow-up 
 
 β-coefficient** 
 
P-value 
All tertiles of serum 25-hydroxyvitamin D -0.300 <0.0001 
   
Highest 2 tertiles of serum 25-
hydroxyvitamin D 
-0.120 0.283 
   
* Tertile 1: 5.01 – 20.57 ng/mL, Tertile 2: 20.58 – 29.87 ng/mL, Tertile 3: 29.88 – 74.74 
ng/mL  
** The β–coefficient represents the difference in FEV1 decline per each ng/mL increase 
in serum 25-hydroxyvitamin D
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Supplemental Table 2.1.  Baseline Characteristics of Health ABC Participants by 
Tertile of Serum 25-hydroxyvitamin D* 
 
 Tertile 1 Tertile 2 Tertile 3 
  (n =671) (n = 672) (n = 672) 
 Age, years (SD)  73.5 (2.9) 73.7 (2.9) 73.6 (2.8) 
 Females (%) 318 (47%) 352 (52%) 354 (53%) 
 Blacks (%) 411 (61%) 207 (31%) 110 (16%) 
 Memphis, TN site (%) 354 (53%) 340 (51%) 342 (51%) 
 Former Smokers (%) 298 (44%) 306 (46%) 326 (49%) 
 Current Smokers (%) 88 (13%) 149 (6.5%) 166 (5.5%) 
 Packyears (SD) 17.7 (25.7) 16.8 (25.5) 17.9 (28.4) 
 Height, cm (SD)  166.1 (9.2) 167.0 (9.0) 167.1 (9.3) 
 BMI, kg/m2 (SD)  28.8 (5.2) 27.2 (4.3) 26.1 (3.8) 
FEV1 at baseline, mL (SD)  2135 (573) 2321 (613) 2397 (610) 
FEV1 ratio at baseline (SD)  75.92 (6.01)  75.85 (5.63)  75.36 (5.52)  
  
Serum 25-hydroxyvitamin D, 
ng/mL (SD)  
15.3 (3.69) 
 
25.2 (2.64) 
 
37.5 (6.34) 
 
* Tertile 1: 5.01 – 20.57 ng/mL, Tertile 2: 20.58 – 29.87 ng/mL, Tertile 3: 29.88 – 74.74 
ng/mL 
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Supplemental Table 2.2.  Cross Tabulation of Tertile of Serum 25-hydroxyvitamin D 
and of Tertile of FEV1 
 
Tertile of serum 
25-hydroxyvitamin D 
Tertile 1 of FEV1 
(620 – 1964mL) 
Tertile 2 of FEV1 
(1965 – 2518 mL) 
Tertile 3 of FEV1 
(2521 – 4432 
mL) 
    
Tertile 1  
(5.01 – 20.57 ng/mL) 
276 234 161 
    
Tertile 2  
(20.58 – 29.87 ng/mL) 
209 224 239 
    
Tertile 3  
(29.88 – 74.74 ng/mL) 
186 214 272 
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Supplemental Table 2.3.  Number of Participants with Only Baseline FEV1 or all Four 
FEV1 Measurements by Tertile Serum 25-hydroxyvitamin D 
 
Tertile of serum 
25-hydroxyvitamin D 
# participants with only 
baseline FEV1 (%) 
Number of participants with 
four FEV1 measurements 
(%) 
   
Tertile 1  
(5.01 – 20.57 ng/mL) 
160 (23.9%) 254 (37.9%) 
   
Tertile 2  
(20.58 – 29.87 ng/mL) 
113 (16.8%) 306 (45.5%) 
   
Tertile 3  
(29.88 – 74.74 ng/mL) 
89 (13.2%) 331 (49.3%) 
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CHAPTER 3 
GENETIC VARIANTS IN VITAMIN D METABOLIC PATHWAY GENES ASSOCIATED 
WITH PULMONARY FUNCTION 
 
 
Abstract 
Vitamin D is hypothesized to play role in lung health as reflected by pulmonary function, 
but evidence from observational studies is mixed.  The association of genetic variants in 
vitamin D metabolism genes with lung function (FEV1 and FEV1/FVC) was investigated 
in the Health, Aging, and Body Composition (Health ABC) study.  Single nucleotide 
polymorphisms (SNPs) in GC, CYP2R1, CYP27B1, VDR, RXRA, and CYP24A1 were 
tested in linear regression models stratified by race.  In African-American participants, 
rs3886163 in CYP24A1 was associated with FEV1, and rs11168293 in VDR was 
associated with FEV1/FVC, at a false discovery rate (FDR) < 0.2.  Two haplotypes in 
CYP24A1 were associated with FEV1 in African-Americans with permuted P < 0.05.  An 
interaction between serum 25-hydroxyvitamin D and two SNPs in RXRA in European-
Americans reached the FDR threshold (< 0.2).  Participants homozygous for the minor 
allele on rs6537944 (vs. wild type homozygotes and heterozygotes) had a lower 
FEV1/FVC ratio only in the presence of low serum 25-hydroxyvitamin D (< 20 ng/mL); at 
higher levels of serum vitamin D there was little or no association of the SNP with the 
ratio phenotype. These findings provide novel evidence supporting a role for vitamin D 
in lung function relevant to obstructive disease. This study identifies genetic variants 
and gene-environment interactions that may increase risk for compromised pulmonary 
function.   
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Introduction 
 Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of 
death in the United States and over 12 million Americans have prevalent disease [1].  
COPD is characterized by poor lung function, and is diagnosed using the forced 
expiratory volume in the first second (FEV1) and the forced vital capacity (FVC).  The 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines mild or stage I 
COPD as an FEV1/FVC ratio < 0.7 and an FEV1 ≥ 80% predicted (by age, race, gender, 
and height) [1].  Smoking is the primary risk factor for COPD, but not all smokers 
develop the disease, and about 15% of COPD-related mortality arises in persons who 
have never smoked [2].  Thus, other genetic and/or environmental factors are 
postulated to affect lung function and to contribute to COPD risk.  Research is needed 
to identify these contributing factors in order to inform COPD prevention and treatment 
efforts.   
 Several lines of evidence suggest a role for vitamin D as an environmental factor 
in the maintenance of lung function.  Inadequate vitamin D levels are common and often 
overlooked in routine medical visits [3]; if a connection with lung function is established, 
this modifiable environmental factor could affect a large proportion of the at-risk 
population for COPD.  Vitamin D is formed naturally in the skin from exposure to 
sunlight, or can be consumed through diet and supplements [4,5].  In the liver, the 25-
hydroxylase (CYP2R1) converts vitamin D to the major circulating form, 25-
hydroxyvitamin D [6].  In plasma, 25-hydroxyvitamin D is transported via the vitamin D 
binding protein (encoded by GC).  25-hydroxyvitamin D is converted by 1-alpha-
hydroxylase (CYP27B1) to the more active form, 1,25-dihydroxyvitamin D, which is 
formed in the kidney, and is hypothesized to form in individual tissues for endocrine and 
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paracrine/autocrine activity, respectively [7].  In addition to its more commonly known 
role in calcium homeostasis, the active form of vitamin D acts as a steroid hormone, 
directly modulating gene expression by interaction with the vitamin D receptor (VDR) 
and its heterodimer partner, the retinoid X receptor (RXRA), with subsequent binding to 
vitamin D response elements in DNA [8,9].  Finally, the active form of vitamin D is 
degraded by the 24-hydroxylase (CYP24A1) to form 1,24,25-trihydroxyvitamin D.   
Serum concentrations of 25-hydroxyvitamin D are more stable over time than the active 
form, and this metabolite is used as the primary biomarker of vitamin D nutritional 
exposure in epidemiological studies [10].   
 A positive association between serum 25-hydroxyvitamin D and pulmonary 
function (FEV1 and FVC) was reported in a cross-sectional study of adult participants in 
the Third National Health and Nutrition Examination Survey (NHANES III) [11].  
However, a recent cross-sectional study in the Hertfordshire Cohort reported no 
association between serum 25-hydroxyvitamin D and lung function [12].  A recent case-
control study reported no difference in initial serum 25-hydroxyvitamin D comparing 
smokers with subsequent rapid decline in FEV1 to smokers with slow decline, but the 
study did not account for race or other confounding factors [13].  The conflicting results 
of the observational studies leave the role of vitamin D in lung health an open question, 
and raise the possibility that vitamin D levels may be a proxy for general good health 
and not a causal player.     
 Genotype is unaffected by ‗lifestyle‘ confounding that affects the vitamin D—
disease association in traditional epidemiologic studies.  In the case that genotype is a 
key determinant of exposure status and only a direct cause of disease through the 
exposure pathway, the use of genetic data as an independent measure of exposure 
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status strengthens causal inference [14].  The SUNLIGHT consortium reported 
significant contribution of variation in transport and metabolism genes to circulating 25-
hydroxyvitamin D concentrations [15], and high heritability of serum vitamin D 
concentrations [16], supporting the use of genetic proxies for exposure status in 
epidemiologic studies.  Moreover, some genetic variants may work by altering net 
vitamin D function independent of serum 25-hydroxyvitamin D concentrations.  Several 
studies reported that single nucleotide polymorphisms (SNPs) in the gene encoding the 
vitamin D binding protein (GC) were associated with COPD risk [17,18,19,20,21].  
These variants alter binding affinity for circulating forms of vitamin D, which could affect 
delivery to target cells [22].  
 The present study investigated the hypothesis that variants in candidate genes in 
the vitamin D metabolic pathway, which produce sustained and long-term differences in 
vitamin D nutriture, predict lung function phenotypes.  The hypothesis was studied using 
data from the Health, Aging, and Body Composition (Health ABC) Study, and 
considering single SNP associations, haplotypes, and interactions with serum 25-
hydroxyvitamin D concentrations.   
 
Materials and Methods 
Study Population 
 The Health ABC study, a longitudinal cohort study that tracks a period of rapid 
health transitions in the elderly, comprises 3,075 African-American and European-
American men and women (46% of women and 37% of men were African-American).  A 
random sample of European-American and all African-American Medicare-eligible 
persons residing in ZIP codes from the metropolitan areas surrounding Pittsburgh, PA 
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and Memphis, TN were invited to join the study.  Eligibility criteria included: aged 70 to 
79 years in the recruitment period (March 1997 to July 1998); self-report of no difficulty 
walking one-quarter of a mile or climbing 10 steps without resting; no difficulty 
performing basic activities of daily living; no reported use of a cane, walker, crutches or 
other special equipment to ambulate; no history of active treatment for cancer in the 
prior 3 years; and no plan to move out of the area in the subsequent 3 years.  Further 
details of this population are described elsewhere 
(http://www.nia.nih.gov/ResearchInformation/ScientificResources/HealthABCDescription
.htm). 
Pulmonary Function Measurement 
 FEV1 and FVC were measured using NIOSH spirometry systems at year 1, 5, 8, 
and 10 follow-up visits (corresponding to 0, 4, 7 and 9 years on study).  Measurement 
quality was assessed using American Thoracic Society standardization of spirometry 
guidelines [23,24].  Acceptable quality was defined as having no early coughs, no early 
termination, limited extrapolated volume, and ≤ 200 ml between the two best FEV1 
measurements at each visit.   
Vitamin D Measurement 
 Serum 25-hydroxyvitamin D was assessed in stored serum from the year 2 visit 
using the Diasorin RIA assay according to manufacturer specifications (assayed in 
November 2006).  The inter-assay coefficient of variation for the measurement of 25-
hydroxyvitamin D was 6.78% for log-transformed values [25]. 
Genotyping 
 Genomic DNA was extracted using the PUREGENE® DNA Purification Kit from 
buffy coat obtained at the baseline exam visit.  Genotyping was performed by the 
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Center for Inherited Disease Research (CIDR) using the Illumina Human1M-Duo 
BeadChip system.  Samples were not included in cases of sample failure, genotypic sex 
mismatch, and first-degree relative of an included individual based on genotype data.  A 
total of 1,151,215 SNPs were genotyped for genome-wide association studies in 2,802 
unrelated individuals (1,139 African-Americans and 1,663 European-Americans).  For 
this study, a total of 190 SNPs in African-Americans and 152 SNPs in European-
Americans in GC, CYP2R1, CYP27B1, VDR, RXRA, and CYP24A1 were examined for 
association with pulmonary function (Supplementary Tables 3.1 and 3.2). 
Data Analysis 
 Analysis of the association of SNPs with pulmonary function was stratified by 
race and included 737 African-Americans and 1,259 European-Americans from the 
Health ABC cohort.  Participants with low spirometry quality control scores, missing 
smoking status and/or history, prevalent COPD by spirometry (defined as FEV1 and 
FEV1/FVC ratio below the lower limit of normal), report of prevalent doctor-diagnosed 
asthma, or missing the first two principal components accounting for genetic 
substructure were excluded from analysis (Table 3.1).  For vitamin D interaction 
analysis, participants missing serum 25-hydroxyvitamin D measurements were also 
excluded.   
 All associations (single SNP, haplotype, and interactions) were adjusted for 
gender, smoking status, height, study site, and the first two principal components of 
genetic substructure, as covariates.  To study single SNP associations with FEV1 and 
FEV1/FVC at study baseline, linear regression analyses considered additive, dominant, 
or recessive models using PLINK v1.07 [26].   Individuals missing more than 30% of 
genotypes or SNPs missing more than 10% of genotypes were excluded, and only 
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SNPs with a minor allele frequency > 1% (or, > 5% in recessive models) and in Hardy-
Weinberg equilibrium were studied.  Associations were considered significant at a false 
discovery rate (FDR) of < 0.2 to account for multiple testing.   
 For SNPs with a nominal p < 0.01, further analyses considered haplotypes.  
Phase was imputed and haplotypes were identified in the African-American and 
European-American Health ABC populations using Haploview version 4.2 [27].  In 
Haploview, linkage disequilibrium blocks were defined by the confidence interval-based 
algorithm of Gabriel et al [28]. Haplotype associations were assessed using PLINK 
linear regression with an additive model, with the same covariates as above. The 
max(T) permutation procedure was used with 10,000 permutations to correct for 
multiple testing.   Haplotype allele frequencies < 5% were excluded from analysis, and 
all other exclusions were the same as for the single SNP analysis. 
 The association of serum 25-hydroxyvitamin D concentration and SNP genotype 
was assessed using PLINK.  For genes downstream of 25-hydroxyvitamin D production, 
the interaction of gene variants and serum 25-hydroxyvitamin D level in relation to lung 
phenotypes was considered, using product terms added to linear regression in SAS 
version 9.2 and considering the same covariates and exclusion criteria as above.  
 
Results 
Population Characteristics 
 A total of 737 African-American and 1,259 European-American participants from 
the Health ABC cohort were included to investigate the associations of SNPs in vitamin 
D metabolic pathway genes with measures of pulmonary function related to obstructive 
lung disease (Table 3.1).   Excluded from analysis were 544 African-American and 535 
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European-American participants with low spirometry quality control scores, missing 
smoking status and/or history, report of prevalent doctor-diagnosed asthma, missing 
principal component, or prevalent spirometry-defined COPD (Supplemental Table 3.3).  
Characteristics of included and excluded study participants were similar.  As expected 
due to exclusion of participants with lung disease, excluded African-American and 
European-American participants had lower FEV1 than included participants.   
 
Single SNP Associations 
 Analysis of the associations of SNP variants in vitamin D metabolic pathway 
genes with FEV1 and FEV1/FVC revealed two significant associations in African-
American study participants with false discovery rate (FDR) < 0.2.  An intronic SNP in 
CYP24A1, rs3886163, was associated with FEV1 (beta coefficient = 116.1, p = 0.001, 
FDR = 0.125; dominant model).  An exonic (or 5‘ UTR depending on splice variant) SNP 
in VDR, rs11168293, was associated with FEV1/FVC (beta coefficient = 4.867, p = 
0.002, FDR = 0.174; recessive model).  Neither of these SNPs was statistically 
significantly associated with serum levels of 25-hydroxyvitamin D concentrations 
(Supplemental Table 3.4).   
 In African-American participants, a total of seven SNPs with nominal p < 0.01 
were selected for further haplotype analysis (two SNPs in CYP24A1 for FEV1 and five 
SNPs in VDR, CYP24A1, and GC for FEV1/FVC; Table 3.2).  In European-American 
participants, no SNPs reached the preset FDR threshold of < 0.2, but a total of four 
SNPs with nominal p < 0.01 (two SNPs in GC and CYP24A1 for FEV1 and two SNPs in 
VDR for FEV1/FVC) were selected for further haplotype analysis (Table 3.3).     
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Haplotype Analysis 
 Haplotype blocks in regions surrounding SNPs with nominal p < 0.01 were tested 
for association with FEV1 and FEV1/FVC in African-American and European-American 
participants.  In African-American participants, 7 SNPs were the starting point to 
construct 4 haplotype blocks in 3 genes.  In European-American participants, 4 SNPs 
were the starting point to construct 4 haplotype blocks in 3 genes.  In both populations 
the GC, CYP24A1, and VDR genes were investigated in the haplotype analysis.  From 
43 haplotypes in 8 haplotype blocks, 2 haplotypes in CYP24A1 were associated 
(permuted p-value < 0.05) with FEV1 in African-Americans (Figure 3.1).  Haplotypes in 
two separate blocks in CYP24A1 were statistically significantly associated (permuted p-
value < 0.05) with FEV1 (Table 3.4).  Haplotype block 4 of CYP24A1 consisted of two 
SNPs and three separate haplotypes.  This block contained rs3886163, which was 
significantly associated with FEV1 in single SNP analysis.  The ‗AT‘ haplotype in block 4 
of CYP24A1 (vs. all other block 4 haplotypes, combined) was associated with higher 
FEV1 (102 mL, p = 0.001, permuted p = 0.006) (Table 3.4.) The ‗CA‘ haplotype in block 
7 of CYP24A1 (vs. all other block 7 haplotypes, combined) was associated with lower 
FEV1 (-83.3mL, p = 0.005, permuted p = 0.024).  No other haplotypes were statistically 
significantly associated with FEV1 or FEV1/FVC in African-American or European-
American participants. 
 
Vitamin D Interactions with SNP Genotype 
 Two statistically significant interactions between SNP genotypes in RXRA and 
serum 25-hydroxyvitamin D were detected in European-American participants.  Thus, 
the combination of a lower serum 25-hydroxyvitamin D concentration and a ‗CC‘ or ‗CT‘ 
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genotype for rs6537944 was associated with decreased FEV1 (p = 0.002, FDR = 0.114) 
(Figure 3.2a, Supplemental Table 3.5).  European-American participants with a ‗CC‘ 
genotype for rs4842196 had a lower FEV1/FVC ratio only in the presence of a lower 
concentration of serum 25-hydroxyvitamin D (p = 0.001, FDR = 0.042) (Figure 3.2b, 
Supplemental Table 3.6).  For both SNPs, the difference in lung function between major 
and minor allele carriers disappeared as serum levels of 25-hydroxyvitamin D 
increased, thus the SNP effects were attenuated with increasing vitamin D nutriture. 
 
Discussion 
 Genetic variants in the vitamin D metabolic pathway, specifically in the VDR, 
CYP24A1 and RXRA genes, were associated with pulmonary function. In African-
American participants, a SNP in VDR was significantly associated with FEV1/FVC at a 
false discovery rate cutoff of 0.2.  No haplotypes in VDR were significantly associated 
with lung function, but genotyping in this study may not be dense enough to estimate 
haplotype effects accurately.  A SNP in CYP24A1 was associated with FEV1 (FDR < 
0.2), also in African-American participants.  Haplotype analysis of the CYP24A1 gene 
revealed one haplotype that was statistically significantly associated (permuted p < 
0.05) with higher FEV1, and a second haplotype that was associated with lower FEV1.  
No SNPs or haplotypes were statistically significantly associated with pulmonary 
function in European-American participants, but serum 25-hydroxyvitamin D levels 
modified the association of SNPs in the RXRA with FEV1 and FEV1/FVC in this 
population. 
 Despite the limited and conflicting epidemiological evidence on the association of 
serum vitamin D and lung function, molecular studies consistently support a plausible 
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role for vitamin D in pulmonary function. The decline in lung function that is a key 
feature in the pathogenesis of COPD is hypothesized to occur through processes of 
chronic inflammation and tissue remodeling [29,30]. Molecular evidence shows that 
vitamin D modulates the expression of genes involved in both processes, both in vitro 
and in animal models [7,31,32,33].  Only one study has examined molecular outcomes 
following vitamin D supplementation in humans: British Bangladeshi men supplemented 
with vitamin D (four intramuscular injections of 500 IU in one year) had decreased 
circulating levels of biomarkers of inflammation and tissue remodeling in relation to pre-
supplementation values [34], supporting the molecular evidence on mechanisms 
whereby vitamin D may affect non-bone outcomes.   
 
Putative Mechanisms for CYP24A1Variants 
 Elevated CYP24A1 expression is reported for many cancers, including cancer of 
the lung, and is associated with poor prognosis; the hypothesized mechanism is that 
higher expression leads to more removal of 1,25-dihydroxyvitamin D from regions 
surrounding tumors, with detrimental consequences [35].  No other associations of 
CYP24A1 with lung phenotypes have been reported.  CYP24A1 degrades the active 
form of vitamin D, thus a genetic variant affecting activity or expression of the enzyme is 
hypothesized to lead to differences in 1,25-dihydroxyvitamin D levels, and in turn, may 
affect phenotype.  Dominant negative-acting splice variants for CYP24A1 that are 
catalytically inactive, but retain substrate binding ability, have been reported in several 
cell types [36,37]; thus, another potential mechanism for SNP effects is via alteration of 
binding activity or expression of these splice variants.   
 CYP24A1 degrades both 1,25-dihydroxyvitamin D and circulating 25-
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hydroxyvitamin D [38], so genetic variants affecting CYP24A1 activity may lead to lower 
concentrations of the circulating biomarker.  In a candidate gene analysis, the 
SUNLIGHT Consortium identified a SNP near CYP24A1 (rs6013897) that was 
associated with serum 25-hydroxyvitamin D concentration [15]. In the current study, 
there was little or no association between serum 25-hydroxyvitamin D concentration and 
CYP24A1 variants; this negative finding is consistent with no true association or with 
SNP effects on 25-hydroxyvitamin D concentration that are subtle and within the noise 
of day-to-day variation.  The possibility remains that CYP24A1 variants alter 1,25-
dihydroxyvitamin D levels, and that even small changes may have large effects due to 
the higher potency of the active form.  
 
Putative mechanisms for VDR variants  
 Polymorphisms in VDR were associated with lung phenotypes in prior studies, 
including sarcoidosis [39], asthma [40,41], pulmonary tuberculosis [42], and non-small 
cell lung cancer [43].  Genetic variants in VDR are expected to be independent of 25-
hydroxyvitamin D levels, since such variants likely affect function of 1,25-
dihydroxyvitamin D as a regulator of gene expression.  Thus, the effects of these 
genetic variants would not be detected in an epidemiologic study using 25-
hydroxyvitamin D as a biomarker for vitamin D status.    
 
Race Differences in Genetic Associations 
 It is noteworthy that genetic variants associated with lung function were detected 
in African-American participants, since this group is already at increased risk for poor 
vitamin D status.  Skin pigmentation interferes with vitamin D formation from exposure 
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to sunlight [44], and an estimated 32% of African Americans are deficient (<12 ng/mL 
serum 25-hydroxyvitamin D) in vitamin D [45]. Thus, the study may have more 
sensitivity to detect genotype—phenotype associations in African Americans if such 
associations are strengthened in the presence of low vitamin D nutriture. In addition, the 
African American population has greater genomic variation, and thus the genotype—
phenotype associations may be more readily detected in the African-American 
subgroup. No interactions with serum 25-hydroxyvitamin D were observed in African-
American participants, and the left-shifted distribution of serum concentrations may be a 
contributing factor.  
 
SNP—Serum Vitamin D Interactions: Gene x Environment  
 In European-American participants, significant interactions between serum 25-
hydroxyvitamin D concentration and genotype for two RXRA SNPs were observed, one 
associated with FEV1 and the other with FEV1/FVC.    Individuals carrying the minor 
alleles for these SNPs are more likely to have low lung function if they also have 
relatively low levels of serum 25-hydroxyvitamin D.  Carriers of the alleles had lower 
lung function even at 20 ng/mL 25-hydroxyvitamin D, which is not conventionally 
considered to be a deficient level (Dietary Reference Intakes for Calcium and Vitamin D, 
Institute of Medicine:  http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-
Calcium-and-Vitamin-D.aspx).  However, minor allele carriers with the highest 25-
hydroxyvitamin D levels had lung function that was no different from participants with 
the major allele, suggesting that nutritional intervention may be effective at mitigating 
lung function decline. SNPs in RXRA were only significantly associated with lung 
function in combination with 25-hydroxyvitamin D, which suggests that the mechanism 
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of action for genetic variants in RXRA affecting lung function may be through the vitamin 
D metabolic pathway.  This is important because RXRA has many functions as a 
regulator of gene expression, and binds other heterodimeric partners besides VDR.  
However, an interaction with 25-hydroxyvitamin D level is consistent with genetic 
variation that alters 1,25-dihydroxyvitamin D or VDR binding; if the slope of the linear 
portion of the binding curve differs due to genetic variation, low serum 25-
hydroxyvitamin D levels would affect lung function, with no detectable differences by 
genotype at relatively high serum 25-hydroxyvitamin D concentrations when binding is 
saturated.     
 Observational studies of vitamin D are open to criticism because vitamin D 
nutriture is often correlated with general health; moreover, the possibility of reverse 
causation cannot be eliminated in cross-sectional studies, since illness can lead to 
lifestyle changes preventing sun exposure.  In addition, a crucial limitation of association 
studies of vitamin D is the reliance on a single measurement of serum 25-
hydroxyvitamin D.  Attempts to adjust statistically for seasonal variation of serum 25-
hydroxyvitamin D levels may not be completely effective, and a single measurement 
may not accurately reflect an individual‘s average status over the time period of interest 
(e.g., during adulthood as chronic disease is developing).  The approach in the current 
study addresses these limitations, considering genetic variants as instrumental 
variables to provide an alternative, and theoretically more accurate, assessment of the 
cumulative effect of a long-term alterations in vitamin D functionality.  The studied genes 
function downstream of serum 25-hydroxyvitamin D, affecting levels of 1,25-
dihydroxyvitamin D and/or its interaction with the VDR/RXR heterodimer. Thus the 
current study provides strong evidence supporting a role for vitamin D in lung function.   
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 Genetic variants in the vitamin D metabolic pathway genes, specifically in VDR 
and CYP24A1, were associated with lung function phenotypes in African-Americans. 
Gene-environment interactions, specifically SNP associations that were conditional on 
serum 25-hydroxyvitamin D concentrations, were identified in European-Americans for 
the RXRA gene.  The results support a beneficial role for vitamin D in lung health. 
These results provide novel insights into molecular mechanisms governing lung 
function, and may help to identify at-risk individuals, and nutritional and/or 
pharmacological interventions for COPD. 
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Table 3.1.  Descriptive Characteristics of Health, Aging and Body Composition Study 
Participants  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*mean, SD shown unless otherwise indicated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variable: 
African-Americans 
(N = 737 ) 
European-Americans 
(N = 1259) 
 Age, years*  73.4 (2.9) 73.8 (2.9) 
 Females (%) 397 (53.9) 681 (54.1) 
 Memphis, TN site (%) 331 (44.9) 625 (49.6) 
 Former Smokers (%) 311 (42.2) 623 (49.5) 
 Current Smokers (%) 108 (14.7) 69 (5.5) 
 Packyears of cigarette smoking  15.4 (21.9) 19.0 (28.9) 
 Height, cm  165.8 (9.3) 167.2 (9.3) 
FEV1, mL   2051 (538) 2408 (617) 
FEV1 ratio   76.4% (6.1) 75.3% (5.5) 
Serum 25-hydroxyvitamin D, ng/mL  21.1 (10.9) 29.0 (10.1) 
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Table 3.2.  Statistically Significant SNPs (FDR < 0.2) and SNPs Selected for Haplotype Analysis 
(p < 0.01) in 737 African-American Participants in the Health ABC Study. 
 
Phen SNP Gene CHR Location 
MAF 
(%) Model B-coeff P-value FDR 
FEV1 rs3886163 CYP24A1 20 intron 12.3 dominant 116.1 0.001 0.125
*
 
 rs4809960 CYP24A1 20 intron 13.2 additive -85.2 0.004 0.394 
FEV1/FVC 
rs11168293 VDR 12 
Exon/ 
5'UTR 15.0 recessive 4.867 0.002 0.174
*
 
 rs3890733 VDR 12 intron 14.8 recessive 4.695 0.004 0.234 
 rs6022999 CYP24A1 20 intron 37.6 recessive 1.786 0.006 0.292 
 rs222046 GC 4 intron 12.9 additive -1.334 0.004 0.643 
 rs4364228 GC 4 intron 39.3 dominant -1.253 0.007 0.692 
Abbreviations: Phen, Phenotype; SNP, single nucleotide polymorphism; CHR, chromosome; 
MAF, minor allele frequency; B-coeff, beta coefficient; FDR, False Discovery Rate. 
* FDR < 0.2 
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Figure 3.1 
CYP24A1
Chr 20
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Figure 3.1.  Haplotype structure and single SNPs in CYP24A1.  Linkage 
disequilibrium map of CYP24A1, with black/gray shading representing regions of high 
LOD and high D‘ with darker shades representing higher D‘, and regions with pink 
shading representing low LOD and high D‘ with darker shades representing higher LOD. 
 Gene annotation is shown at the top of the figure, with a Manhattan plot in between 
showing -log(p-value) for the association of single SNPs with FEV1.  SNPs with 
unadjusted p < 0.01 are shown (*), as well as haplotype blocks surrounding these SNPs 
(brackets, labeled Block 4 and Block 7).  
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Table 3.3.  SNPs Selected for Haplotype Analysis (p < 0.01) in 1,259 European-
American Participants in the Health ABC Study*.  
 
*Note, no SNPs in European-Americans reached the FDR preset threshold of 0.2 
 
Abbreviations: SNP, single nucleotide polymorphism; CHR, chromosome; MAF, minor 
allele frequency; LOC, location; B-coeff, beta coefficient; FDR, False Discovery Rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phenotype SNP Gene CHR LOC 
MAF  
(%) Model B-coeff P-value FDR 
FEV1 rs705120 GC 4 intron 47.0 recessive -77.44 0.010 0.697 
 rs6097801 CYP24A1 20 3' UTR 27.5 dominant -72.84 0.007 0.972 
   
FEV1/FVC rs2254210 VDR 12 intron 34.2 dominant 0.862 0.006 0.455 
 rs2853564 VDR 12 intron 13.7 dominant 0.8611 0.006 0.455 
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Table 3.4.  Statistically Significant Haplotypes (Permuted P < 0.05) in CYP24A1 Gene 
for the FEV1 Phenotype in 737 African-American Participants in the Health ABC Study. 
 
* B-coefficient is for each haplotype compared with combination of other haplotypes in 
haplotype block with an allele frequency ≥5%  
† Permuted p-value is the empirical p-value from the max(T) permutation procedure, 
which controls the family-wise error rate. 
‡ Permuted p-value < 0.05 
Abbreviations: SNP, single nucleotide polymorphism; HAP, haplotype; FREQ, 
frequency; B-coeff, beta coefficient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HAP 
 Block 
# SNPs  
in HAP SNP 1 SNP 2 HAP 
FREQ 
(%) B- Coeff* P-value 
Permuted  
p-value† 
4 2 rs6022994 rs3886163 AT 11.7 102 0.001 0.006 ‡ 
    CC 34.4 -31.6 0.140 0.496 
    AC 53.9 -13.9 0.495 0.944 
7 2 rs4809960 rs2296241 CA 13.3 -83.3 0.005 0.024 ‡ 
    TA 36.3 14.6 0.488 0.941 
    TG 50.4 26 0.207 0.649 
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Figure 3.2.  Statistically Significant Interaction of SNPs in RXRA and Serum 25-
hydroxyvitamin D with FEV1 in European-American Participants.  (A) Predicted 
FEV1 for each genotype of rs6537944 at different serum levels of 25-hydroxyvitamin D. 
Under dominant model, black bars comprise minor allele carriers (CC/CT genotypes), 
and gray bars comprise wildtype homozygotes (TT).  (B) Predicted FEV1/FVC for each 
genotype of rs4842196. Under recessive model, black bars comprise homozygote 
variant genotype (CC), and gray bars comprise wildtype (CA/AA genotypes). 
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Supplemental Table 3.1.  SNPs in Vitamin D Metabolic Genes Analyzed for Association 
with Pulmonary Function in African-American Participants of the Health ABC Study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Gene names are column headings; rs numbers in columns under gene name show 
SNPs selected for analysis for each gene 
 
GC RXRA CYP2R1 VDR CYP27B1 CYP24A1 
rs222048 rs11185647 rs11023374 rs2525046 rs11172325 rs6097801 
rs705117 rs7855881 rs7935792 rs2525045 rs8176353 rs2762931 
rs2282679 rs872298 rs1993116 rs881383 rs8176351 rs2762932 
rs3755967 rs10881576 rs10500804 rs11574143 rs8176348 rs6097805 
rs222047 rs3818740 rs7129781 rs11574138 rs4646537 rs6068810 
rs222046 rs12339187 rs12794714 rs9729 rs8176347 rs6097807 
rs16846912 rs10881578 rs2060793 rs7967673 rs4646536 rs16999060 
rs1491709 rs10881580  rs7954412 rs11172327 rs4809957 
rs705120 rs4917354  rs11574127 rs10877012 rs2762934 
rs9016 rs914853  rs3858733 rs703842 rs927650 
rs4588 rs11185659  rs3847987  rs1570669 
rs7041 rs12348547  rs739837  rs1570670 
rs4752 rs7041449  rs731236  rs2296239 
rs4364228 rs7853934  rs7975232  rs6022990 
rs6835052 rs7048602  rs11574114  rs912505 
rs3737549 rs10881582  rs757343  rs6127119 
rs222014 rs11185660  rs1544410  rs6097816 
rs222016 rs7039190  rs7967152  rs6022993 
rs222020 rs34312136  rs2239185  rs6022994 
rs222023 rs34399387  rs2239184  rs3886163 
rs16847015 rs35079168  rs11168266  rs6068816 
rs1491718 rs4501664  rs11168267  rs6013905 
rs1155563 rs11102986  rs11168268  rs6022995 
rs1352844 rs11103473  rs11574077  rs4809958 
rs1352845 rs10776909  rs2248098  rs3787554 
rs2298849 rs6537998  rs2239182  rs3787555 
rs3733359 rs7869783  rs2107301  rs2244719 
rs16847024 rs1805352  rs2283342  rs3787557 
 rs3132296  rs2239181  rs2762941 
 rs3118529  rs1540339  rs2181874 
 rs731516  rs2239179  rs4809959 
 rs3118536  rs11574065  rs4809960 
 rs7038018  rs12717991  rs2296241 
 rs4240705  rs886441  rs2245153 
 rs11103462  rs2189480  rs2585428 
 rs6537944  rs3819545  rs6022999 
 rs12349076  rs2239186  rs2248359 
 rs3118571  rs11574048  rs2248461 
 rs1536475  rs10735810   
 rs3132294  rs10160907   
 rs877954  rs11574047   
 rs1805343  rs2254210   
 rs4842194  rs11574038   
 GA007945  rs2238136   
 rs1045570  rs2853564   
 rs4842196  rs11574032   
   rs4760648   
   rs11168287   
   rs4328262   
   rs4334089   
   rs4237855   
   rs11574026   
   rs3890733   
   rs11168293   
   rs7136534   
   rs7299460   
   rs11574020   
   rs11574019   
   rs11574017   
   rs11574012   
   rs4516035   
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Supplemental Table 3.2.  SNPs in Vitamin D Metabolic Genes Analyzed for Association 
with Pulmonary Function in European-American Participants of the Health ABC Study. 
 
GC RXRA CYP2R1 VDR CYP27B1 CYP24A1 
rs705117 rs11185647 rs11023374 rs2525046 rs4646537 rs6097801 
rs2282679 rs872298 rs7935792 rs11574143 rs4646536 rs2762931 
rs3755967 rs10881576 rs1993116 rs9729 rs8176345 rs2762932 
rs222047 rs3818740 rs10500804 rs3858733 rs10877012 rs6097805 
rs222046 rs12339187 rs7129781 rs3847987 rs703842 rs6068810 
rs1491709 rs10881578 rs12794714 rs739837  rs6097807 
rs705120 rs10881580 rs2060793 rs731236  rs4809957 
rs4588 rs4917354  rs7975232  rs2762934 
rs7041 rs914853  rs11574114  rs927650 
rs4364228 rs11185659  rs757343  rs1570669 
rs222014 rs7041449  rs1544410  rs1570670 
rs222016 rs7853934  rs7967152  rs2296239 
rs222020 rs7048602  rs2239185  rs912505 
rs222023 rs10881582  rs2239184  rs6127119 
rs16847015 rs11185660  rs11168266  rs3886163 
rs1491718 rs7039190  rs11168267  rs6068816 
rs1155563 rs34312136  rs11168268  rs6013905 
rs1352844 rs35079168  rs11574077  rs4809958 
rs1352845 rs11102986  rs2248098  rs3787554 
rs2298849 rs11103473  rs2239182  rs3787555 
rs3733359 rs10776909  rs2107301  rs2244719 
 rs1805352  rs2283342  rs3787557 
 rs3132296  rs2239181  rs2762941 
 rs3118529  rs1540339  rs2181874 
 rs3118536  rs2239179  rs4809959 
 rs7038018  rs12717991  rs4809960 
 rs4240705  rs886441  rs2296241 
 rs6537944  rs2189480  rs2245153 
 rs3118571  rs3819545  rs2585428 
 rs1536475  rs2239186  rs6022999 
 rs3132294  rs11574048  rs2248359 
 rs877954  rs10735810  rs2248461 
 rs1805343  rs2254210   
 rs1805348  rs2238136   
 rs4842194  rs2853564   
 GA026144  rs11574032   
 rs1045570  rs4760648   
 rs4842196  rs11168287   
   rs4328262   
   rs4334089   
   rs4237855   
   rs11574027   
   rs11574026   
   rs3890733   
   rs11168293   
   rs7136534   
   rs7299460   
   rs11574012   
   rs4516035   
*Gene names are column headings; rs numbers in columns under gene name show 
SNPs selected for analysis for each gene 
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Supplemental Table 3.3. Characteristics of Excluded Participants, the Health Aging and 
Body Composition Study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*mean (SD) unless otherwise noted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variable: 
African-Americans 
(n = 544) 
European-Americans 
(n = 535) 
 Age, years * 73.5 (2.9) 73.8 (2.9) 
 Females (%) 212 (39.0) 258 (48.2) 
 Memphis, TN site (%) 282 (51.8) 310 (57.9) 
 Former Smokers (%) 187 (34.5) 283 (53.1) 
 Current Smokers (%) 99 (18.3) 42 (7.9) 
 Packyears of cigarette 
smoking 18.3 (26.8) 25.1 (33.2) 
 Height, cm   164.8 (9.4) 165.9 (9.5) 
FEV1, mL   1755.5 (593) 1949 (636) 
FEV1 ratio   75.3% (13.8) 72.3% (12.8) 
Serum 25-hydroxyvitamin D, 
ng/mL  20.6 (9.04) 29.1 (13.0) 
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Supplemental Table 3.4. The Association of SNPs with Serum 25-hydroxyvitamin D 
Concentration for Vitamin D Metabolic SNPs associated with Pulmonary Function in 
Prior Models (FDR < 0.2) 
 
SNP Gene CHR LOC 
MAF 
(%) Model 
B-
coeff* P-value FDR 
rs3886163 CYP24A1 20 intron 12.3 additive -1.135 0.138 0.415 
rs11168293 VDR 12 
Exon/ 
5' UTR 15.0 additive 0.501 0.462 1 
Abbreviations: SNP, single nucleotide polymorphism; CHR, chromosome; LOC, 
location; MAF, minor allele frequency; B-coeff, beta coefficient; FDR, False Discovery 
Rate 
 
* The beta-coefficient reflects the difference in serum 25-hydroxyvitamin D 
concentration (ng/mL) per allele copy. 
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Supplemental Table 3.5.  Full Regression Model for Statistically Significant Interaction 
of rs6537944S (RXRA) and Serum 25-hydroxyvitamin D with FEV1 in European-
American Participants.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*β-Coefficients reflect the difference in FEV1 (mL) for variables as follows: 
25-OH-D:  FEV1 difference per unit of 25-OH-D (ng/mL), continuous variable 
rs6537944:  FEV1 difference in 'CC' and 'CT' genotypes versus the homozygous major 
allele, 'TT' 
25-OH-D * rs6537944:  Interaction between rs6537944 genotype and 25-OH-D 
concentration 
Smoking status:  FEV1 difference in current versus former smokers; FEV1 difference in 
former versus never smokers 
Gender:  FEV1 difference in females versus males 
Study site:  FEV1 difference in Pittsburgh, PA participants versus Memphis, TN 
participants 
 
 
 
 
 
 
 
 
Variable β-Coefficient* Standard Error P-value 
Intercept -359.15 499.11 0.4719 
25-OH-D 0.91 1.29 0.4782 
rs6537944 -281.49 100.56 0.0052 
25-OH-D * rs6537944 10.21 3.35 0.0023 
Principal Component 1 -82.00 543.80 0.8802 
Principal Component 2 -3075.01 3957.13 0.4373 
Smoking status -40.45 12.65 0.0014 
Age (years) -27.10 4.14 <.0001 
Gender -443.04 37.70 <.0001 
Height (cm) 29.57 2.01 <.0001 
Study site 102.06 25.89 <.0001 
  83 
Supplemental Table 3.6.  Full Regression Model for Statistically Significant Interaction 
of rs4842196 (RXRA) and Serum 25-hydroxyvitamin D with FEV1/FVC in European-
American Participants.   
*β-Coefficients reflect the difference in FEV1/FVC for variables as follows: 
25-OH-D:  FEV1 difference per unit of 25-OH-D (ng/mL), continuous variable 
rs4842196:  FEV1/FVC difference in the 'CC' genotype versus carriers of the major 
allele, 'CA' and 'AA'   
25-OH-D * rs4842196:  Interaction between rs4842196 genotype and 25-OH-D 
concentration  
Smoking status:  FEV1/FVC difference in current versus former smokers; FEV1 
difference in former versus never smokers 
Gender:  FEV1/FVC difference in females versus males 
Study site:  FEV1/FVC difference in Pittsburgh, PA participants versus Memphis,  
TN participants 
 
 
 
 
 
 
 
 
Variable β-Coefficient* Standard Error P-value 
Intercept 97.79694640 6.62966348 <.0001 
25-OH-D -0.03636600 0.01626905 0.0256 
rs4842196 -8.21227487 2.05614502 <.0001 
25-OH-D*rs4842196 0.22553208 0.06501572 0.0005 
Principal Component 1 -5.32950821 7.19503491 0.4590 
Principal Component 2 -53.61006232 52.31159098 0.3057 
Smoking status -0.76686965 0.16809712 <.0001 
Age (years) -0.17355614 0.05492437 0.0016 
Gender -0.15736494 0.50030684 0.7532 
Height (cm) -0.04748588 0.02667441 0.0753 
Study site 0.54069414 0.34345300 0.1157 
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CHAPTER 4 
ASSOCIATION OF 25-HYDROXYVITAMIN D WITH GENE EXPRESSION IN LUNG 
EPITHELIUM OF HEALTHY NON-SMOKERS 
 
 
Abstract 
 
Vitamin D is known to alter gene expression in vitro, but effects on gene expression in 
humans are unclear.  The primary biomarker of vitamin D status, serum 25-
hydroxyvitamin D, is associated with lung health in epidemiologic studies, but the 
mechanisms mediating vitamin D—lung outcome associations are poorly understood.  
The findings presented herein demonstrate, for the first time, differential gene 
expression in lung epithelial cells associated with serum 25-hydroxyvitamin D in a 
diverse sample of free-living humans.  Microarray analysis investigated the association 
of gene expression in small airway epithelial cells with serum 25-hydroxyvitamin D in 
healthy, adult non-smokers.  The analysis was restricted to candidate genes with prior 
evidence of vitamin D-modulated gene expression in vitro and at least one predicted 
vitamin D response element.  Of the 156 genes studied, 13 genes had statistically 
significant differences in expression by serum 25-hydroxyvitamin D status (p < 0.05), 
and 3 genes (KCNS3, FSTL1, and DAPK1) were significant at a false discovery rate 
cutoff of <0.2. Serum 25-hydroxyvitamin D level explained 40%, 28%, and 14% of 
variance in gene expression in FSTL1, KCNS3, and DAPK, respectively.  Gene 
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ontology and literature analysis of differentially expressed genes supported plausible 
mechanisms for functional roles in asthma, COPD, cancer, and response to infection in 
lung, as well as striking similarities between glucocorticoid responses and vitamin D-
associated gene expression.  The physiological range of 25-hydroxyvitamin D is 
associated with functional differences in molecular outcomes in lung, implying 
mechanisms that explain and strengthen existing associations of 25-hydroxyvitamin D 
with lung health.   
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Introduction 
 
 Recent evidence suggests plausible mechanisms by which vitamin D might affect 
lung health, but there is little research translating animal and cell models to results in 
humans.  The majority of experimental work to date has focused on effects of the active 
metabolite of vitamin D: 1,25-dihydroxyvitamin D.  This metabolite is generated in the 
kidney for systemic circulation, and is hypothesized to be produced locally in many 
tissues, including lung [1].  Because 1,25-dihydroxyvitamin D has a short half-life, is 
tightly regulated, and can be generated in localized tissues for autocrine or paracrine 
effects on demand, it may not be an appropriate serum biomarker for overall vitamin D 
nutriture [2].  Instead, the precursor, 25-hydroxyvitamin D, is accepted as the primary 
biomarker for vitamin D exposure in humans [3].  However, it is not yet clear how 25-
hydroxyvitamin D levels correspond to active 1,25-dihydroxyvitamin D levels in target 
tissues, raising the possibility that effects observed in experimental models may be 
pharmacologic rather than physiologic, due to inappropriate dosing of 1,25-
dihydroxyvitamin D.  Moreover, effects observed in the relatively controlled 
environments of cell and animal models might not be detectable in free-living humans 
experiencing diverse diets and environments.  It is not yet established whether ranges 
of 25-hydroxyvitamin D observed in humans are associated with effects similar to those 
seen in vitro for 1,25-hydroxyvitamin D.   
 Observational studies support an association of physiological ranges of 25-
hydroxyvitamin D with lung outcomes.  A study in the Third National Health and 
Nutrition Examination Survey (NHANES III) reported a positive association between 
serum 25-hydroxyvitamin D concentration and lung function [4].  Low serum 25-
hydroxyvitamin D was associated with higher risk for severe exacerbation of mild-to-
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moderate persistent asthma in children [5], and a higher risk for active tuberculosis [6].  
Evidence that vitamin D plays a role in lung cancer is controversial, but low 25-
hydroxyvitamin D levels were associated with increased lung cancer risk in women and 
young people [7], and high levels of 25-hydroxyvitamin D were associated with 
improved survival in non-small cell lung cancer patients [8].  Reports of an association 
of 25-hydroxyvitamin D with lung outcomes are intriguing, but few studies directly 
addressed mechanisms, which would strengthen the causal inference of population-
level association studies.  
 Vitamin D is postulated to affect lung health through its function as a steroid 
hormone, by directly altering gene expression by interaction with the vitamin D receptor 
(VDR), and subsequent binding to vitamin D response elements in DNA [9].  Cell 
studies have shown that 1,25-dihydroxyvitamin D affects expression of genes related to 
inflammation, cell proliferation, and cell migration [10,11], which suggests plausible 
causal mechanisms for vitamin D associations with asthma, chronic obstructive 
pulmonary disease (COPD), and lung cancer. Only one clinical intervention study 
reported the effect of vitamin D supplementation on inflammation and tissue remodeling 
biomarkers: in vitamin D deficient British Bangladeshi men, injections of non-
hydroxylated vitamin D decreased circulating serum levels of matrix metalloprotease-9 
(68%) and C-reactive protein (23%) in relation to pre-supplementation values [12].  
 Here, we investigate the hypothesis that serum 25-hydroxyvitamin D levels affect 
gene expression in lung epithelial tissues sampled from free-living humans.  We 
examined gene expression by microarray and evaluated gene ontology annotations for 
functional information.  Our results provide evidence that physiological levels of serum 
25-hydroxyvitamin D are associated with differences in gene expression in lung tissue, 
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and that the differences in expression occur in genes from functional categories with 
high relevance to lung health.   
 
Materials and Methods  
 Healthy nonsmoker volunteers were recruited yielding 26 individuals who were 
evaluated at the Weill Cornell Medical College General Clinical Research Center under 
IRB-approved protocols.  Participants underwent physical examinations to confirm the 
absence of disease as described elsewhere [13].  
 Frozen serum samples were sent to the Nutritional Biomarkers Branch of the 
Division of Laboratory Sciences at the Centers for Disease Control and Prevention to be 
assayed for 25-hydroxyvitamin D by liquid chromatography-tandem mass spectrometry.  
Samples were evaluated in parallel with NIST standard SRM 972, and results were 
within 2 standard deviations of NIST target values.  External quality assurance was 
provided through participation in the Vitamin D External Quality Assessment Scheme. 
 Two individuals from the second tertile of 25-hydroxyvitamin D levels were 
excluded from further consideration because serum and cell collections occurred in 
different seasons and more than 120 days apart. The average time between serum and 
epithelial cell collection was 42 ± 40 days, within the 10-week half-life of serum 25-
hydroxyvitamin D [14].   
 Airway epithelial cells were collected by fiberoptic bronchoscopy, as described 
elsewhere [13].  Briefly, small airway epithelial cells were collected with gentle brushing, 
removed from the brush by flicking in ice-cold basal epithelial cell medium, and cells 
were immediately processed to extract RNA [13]. 
 First and second strand cDNA was synthesized from 6 μg of RNA, in vitro 
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transcribed, and fragmented according to Affymetrix protocols.  As a quality control, only 
labeled RNA producing a 3‘ to 5‘ ratio of < 3 on test chips was used.  Samples were 
hybridized to the Affymetrix HG-U133 Plus 2.0 array, washed and treated with reagents 
by the fluidics station, then scanned in duplicate [13].   
 Candidate genes for microarray analysis were identified based on literature 
evidence of regulation by 1,25-dihydroxyvitamin D in squamous epithelial cells [15].  
Candidate genes were required to contain at least one predicted binding site for VDR (a 
DR3 or ER6 response element with up to 1 base mismatch from the consensus 
sequence) [15].  Image files for the arrays were assessed for quality of hybridization by 
comparing 3‘ to 5‘ intensity of transcripts for actin and GAPDH (ratio < 3).  Normalization 
was carried out by GeneChip Robust Multi-Array Average (GC-RMA) using MADMAX 
software (https://madmax.bioinformatics.nl).  Quality control of normalized data was 
evaluated using plots of relative log expression and normalized unscaled standard 
errors to identify array artifacts.  Only probe sets with an interquartile range (IQR) of log2 
normalized values < 0.5 were included in analysis.   
 The statistical significance of fold-changes in expression between the first and 
third tertile of serum vitamin D was calculated using a t-test with Bayesian correction 
(Limma). A threshold of nominal P <0.05 was used to highlight findings for further 
analyses.  Q-values taking into account false discovery rate (FDR) were calculated for 
all candidate genes using SAS version 9.2. Pearson product moment correlation 
coefficients and the variance (R2) in gene expression explained by serum 25-
hydroxyvitamin D were calculated, and included the full range of vitamin D 
concentrations. Gene ontology annotations were obtained from the UniProtKb-GOA 
database (http://www.ebi.ac.uk/QuickGO/), with preference given to IDA annotations 
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(inferred from direct assay) or TAS (traceable author statement) evidence codes.  IEA 
(inferred from electronic annotation) evidence codes were used if no other information 
was available.   
 
Results 
 Healthy, non-smoking adults (n=26) were divided into tertiles of serum 25-
hydroxyvitamin D status (Table 4.1).  Candidate genes were identified based on 
literature evidence of 1,25-dihydroxyvitamin D responsiveness and presence of at least 
one predicted vitamin D response element, as described above.  Further filtering for 
interquartile range (IQR) > 0.5 on log2 scale yielded a final set of 156 candidate genes 
(Supplemental Table 4.1).  
 
Differential Expression in High Compared to Low 25-hydroxyvitamin D Tertiles 
 Among the candidate genes considered, thirteen genes had statistically 
significant (nominal p < 0.05) differences in expression between the first and third 
tertiles of serum 25-hydroxyvitamin D (Table 4.2).  Of these, three genes (KCNS3, 
FSTL1, and DAPK1) were significant at a false discovery rate cutoff of < 0.2.  
Investigating a list of candidate genes selected a priori based on prior evidence of 
vitamin D-regulated expression and VDR binding sites yielded proportionately more hits 
than a random list of all genes. While the expression of 8.3% of candidate genes 
(13/156 genes) was associated with serum 25-hydroxyvitamin D level, considering the 
unfiltered list of all genes passing IQR filtering, only 2.75% (129/4688 genes) were 
associated with serum vitamin D.  Thus, restricting analysis to candidate genes with 
prior in vitro and in silico evidence of vitamin D-regulated expression resulted in a three-
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fold higher percentage of genes with nominally significant differences in expression 
between the highest and lowest tertiles of vitamin D status.   
 To characterize further the relation of serum 25-hydroxyvitamin D level with gene 
expression, the linear association of gene expression with continuous serum 25-
hydroxyvitamin D was assessed for all nominally significant genes (Table 4.3).  The 
percent of variance (R2, from linear regression analysis) explained by serum 25-
hydroxyvitamin D ranged from 8 to 40%; the R2 for FSTL1 was 40%.   
 Further investigation was undertaken to assess the likelihood of a causal 
association of serum vitamin D with gene expression; literature searches were 
conducted to identify evidence of modulation of these genes by vitamin D in cell culture 
or animal models.  Among the thirteen genes with nominally significant associations, 
five genes (DAPK1, CST6, SLITRK6, EMB, and KLF4) had evidence of regulation by 
vitamin D in prior studies [16,17,18,19,20]. 
 
Functional Categories of Differentially Expressed Genes 
 To determine known functions, pathways, and subcellular locations for 
differentially expressed genes, gene ontology categories assigned to each gene in the 
UniProtKb-GOA database were investigated (Table 4.4).  Six genes were integral 
membrane proteins (KCNS3, SLITRK6, TMEM40, EMB, PTGER2, SGPP2), with cell 
surface or extracellular location specified for 5 genes (FSTL1, CST6, KAL1, EMB, 
PTGER2).  The most common functional category was for proteins with metal ion 
binding or channel activity (KCNS3, FSTL1, RSAD2, and DTX4).  Additionally, two 
genes were endopeptidase inhibitors (CST6, KAL1), and two genes were kinases or 
phosphatases (DAPK1, SGPP2).  Roughly half of the genes were involved in pathways 
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of cell fate determination or morphogenesis (KLF4, DTX4, SLITRK6, KAL1, CST6, 
FSTL1), and 3 genes were assigned to pathways of cell proliferation or apoptosis 
regulation (PTGER2, KLF4, DAPK1).   
 
Discussion 
 In a study of free-living, healthy never smokers, we identified 13 genes with 
significantly different lung epithelial cell gene expression between high and low tertiles 
of serum 25-hydroxyvitamin D; three genes (KCNS3, FSTL1, and DAPK1) were 
significant at an FDR cutoff of 0.2.  The variance in gene expression (R2) explained by 
serum vitamin D in linear models exceeded 20% for 8 of the 13 nominally significant 
genes; FSTL1 had the highest R2, at 40%.  The primary analysis was limited to an a 
priori selection of 156 candidate genes, all of which had prior evidence of regulation by 
vitamin D in cultured human squamous epithelial cells and contained putative VDR 
response elements predicted from consensus sequences.  By limiting the analysis to an 
hypothesis-oriented selected set of genes, causal inferences are strengthened, and the 
selected genes were about 3-times more likely to be associated with serum vitamin D 
than an unselected list.  
 Although associations were observed between serum 25-hydroxyvitamin D levels 
and gene expression, this cross-sectional study can not establish causality.  A 
potentially confounding factor, race, also differed by tertile of vitamin D, with a higher 
proportion of European-Americans in the upper portion of the vitamin D distribution and 
higher proportion of African Americans in the lower portion. Given that skin pigmentation 
interferes with vitamin D synthesis in response to sunlight [3], the association of race 
with serum 25-hydroxyvitamin D levels is expected, but because of the small sample 
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size the analysis cannot be limited to single race groups.  Thus, observed associations 
may be partly explained by race rather than by serum vitamin D levels.  A recent 
microarray study comparing gene expression levels in lymphoblastoid cell lines derived 
from European and African populations in the International HapMap Project [21] 
provides evidence that 4 of our 13 nominally significant genes were differentially 
expressed by race: SGPP2, EMB, DAPK1, and RSAD2.  In all four, the direction of the 
expression difference was similar between this study and the HapMap results, thus the 
associations of these genes with serum 25-hydroxyvitamin D may be partly explained 
by race.  However, other literature confirms vitamin D regulation for EMB and DAPK1 in 
cell or animal models [16,19], thus raising the possibility that both race and vitamin D 
levels affect expression of these genes. 
 Functional analysis of the set of 13 differentially expressed genes suggested 
plausible mechanisms for vitamin D function in lung health.  Nearly half of the genes 
were assigned to gene ontology pathways of cell fate determination or morphogenesis, 
thus implying roles in both cancer pathogenesis and airway remodeling typical of 
chronic obstructive pulmonary disease.  Two genes were identified as endopeptidase 
inhibitors, and three were assigned to pathways of cell proliferation or apoptosis 
regulation, supporting possible roles in airway remodeling and cancer.  To further 
explore the mechanisms by which vitamin D-modulated gene expression affects lung 
health, the literature evidence for the 13 differentially expressesd genes is reviewed 
below.   
 
Asthma and COPD 
 Vitamin D is associated with both asthma and COPD, but mechanisms remain 
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unclear [22].  Among the set of 13 differentially expressed genes reported herein, 
several genes were associated with asthma or COPD in past studies, and several 
genes were reported to play a role in airway remodeling and inflammation, which are 
common features in both diseases.  For example, polymorphisms in KCNS3 were 
associated with airway hyperresponsiveness [23], and genetic variation in PTGER2 was 
associated with aspirin-intolerant asthma [24].  PTGER2 was significantly down-
regulated in T cells isolated from children with persistent wheeze [25], but was up-
regulated in the high vitamin D tertile in the current study.  In COPD patients with 
wasting, KLF4 was differentially regulated [26]. Thus, emerging evidence supports a 
role for the identified genes in asthma and COPD. 
 The differentially expressed gene with the lowest nominal P, KCNS3, was up-
regulated by the lung growth factor, bone morphogenetic protein (BMP-2, [27]), which 
plays a role in embryonic lung development and airway branching, and may influence 
inflammatory processes [28].  The second most statistically significant gene, FSTL1, is 
also part of the BMP signaling pathway in gene ontology analysis.  FSTL1 (down-
regulated with high vitamin D) is pro-inflammatory, and leads to up-regulation of the pro-
inflammatory cytokines TNF-alpha, IL-6, and IL-1beta [29].  Several studies report that 
higher serum 25-hydroxyvitamin D level is associated with lower TNF-alpha and IL-6 
[30,31,32].  The findings presented herein suggest that FSTL1 may mediate the 
association of serum 25-hydroxyvitamin D level with the pro-inflammatory cytokines. 
 In examining these results, a common pattern of gene regulation was observed. 
Genes differentially regulated by vitamin D overlapped with the set of genes 
differentially regulated by glucocorticoids.  Dexamethasone, which is used to treat both 
asthma and COPD, is associated with the expression of many of the genes identified by 
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the present study, and there were striking similarities in the direction of effect.  KCNS3 
and FSTL1 are down-regulated by dexamethasone [33,34], and they are similarly down-
regulated in the highest tertile of serum vitamin D.  Glucocorticoid receptor knockout 
mice had 10-fold up-regulated SLITRK6 in lung compared to wild type mice, suggesting 
glucocorticoids normally down-regulate SLITRK6 [35]; similarly, SLITRK6 was down-
regulated in the highest tertile of serum vitamin D. EMB was up-regulated by 
dexamethasone treatment in alveolar macrophages [36], and EMB was similarly up-
regulated in the highest tertile of serum 25-hydroxyvitamin D level.  The combination of 
1,25-dihydroxyvitamin D with dexamethasone has been investigated in vitro as an anti-
inflammatory treatment [37]; our results suggest the strong possibility of synergistic 
effects for this treatment combination.  Indeed, high vitamin D levels have recently been 
associated with improved glucocorticoid response [38]. 
 
Lung Cancer 
 Vitamin D is implicated in carcinogenesis, but its role is controversial, and cancer 
mortality is associated with both very low and very high vitamin D levels [39]. Supporting 
a preventive role for vitamin D, RSAD2, which we found to be up-regulated with high 
serum 25-hydroxyvitamin D level, is also induced by interferon-gamma (IFN-g, [40]), a 
cancer treatment.  In one study, co-administration of 1,25-dihydroxyvitamin D with IFN-g 
produced synergistic responses in lung tumors [41]; up-regulation of the same genes by 
two different mechanisms might explain this synergy.  Another gene up-regulated with 
high 25-hydroxyvitamin D, CST6, is a candidate tumor suppressor gene purported to be 
down-regulated in lung cancer [42].  Similarly, PTGER2, which was up-regulated with 
high serum 25-hydroxyvitamin D level, is down-regulated in 80% of non-small cell lung 
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cancer (NSCLC) cell lines. Methylation of PTGER2 was associated with lower gene 
expression in 58% of NSCLC specimens, compared to only 1% of non-malignant lung 
samples [43].  Up-regulation of KLF4, as observed here in the highest tertile of serum 
25-hydroxyvitamin D level, inhibits lung cancer cell invasion in Matrigel assays [8].   
 The expression of two genes in relation to serum 25-hydroxyvitamin D level 
suggests a cancer promoting role for vitamin D.  SGPP2 was upregulated in the highest 
tertile of serum 25-OH-D, and is also upregulated in NSCLC cell lines with somatic 
mutations in EGFR [44], was associated with vitamin D.DAPK1, which was down-
regulated in the highest serum 25-hydroxyvitamin D tertile, may be a tumor suppressor 
gene; DAPK1 was down-regulated in 72% of squamous cell lung cancer samples [45].  
KAL1, also down-regulated with high serum 25-hydroxyvitamin D level, was down-
regulated in lung adenocarcinomas [46].  Moreover, low expression of KAL1 was 
associated with poor prognosis in NSCLC [47].  Thus, the direction of effect of vitamin D 
on gene expression is inconsistent, and these inconsistencies may contribute to 
resolving the reports of increased cancer risk with excessive vitamin D supplementation.   
 
Lung Response to Infection 
 Serum 25-hydroxyvitamin D concentration is associated with native immune 
response [22], and our results suggest specific mechanisms that could mediate lung 
response to viral and bacterial infections.  For example, the protein product of RSAD2 
(up-regulated with high 25-hydroxyvitamin D levels), is an antiviral protein called viperin, 
strongly induced in lung immune cells in response to viral or Pneumocystis infection 
[36,48]. EMB was up-regulated in the highest tertile of serum 25-hydroxyvitamin D, and 
Pneumocystis infection also up-regulated EMB expression in alveolar macrophages 
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[36].  SGPP2 was up-regulated with high serum 25-hydroxyvitamin D level, and was 
also up-regulated in response to cytomegalovirus infection in a human lung fibroblast 
cell line [49]. These results identify hypotheses for further investigation related to the 
mechanisms through which vitamin D affects immune functioning and response of the 
lung to infection. 
 
Conclusions 
 An abundance of experimental data support effects of 1,25-dihydroxyvitamin D 
on gene expression in vitro.  However, virtually no translational studies have linked the 
often non-physiological concentrations of 1,25-dihydroxyvitamin D used in vitro with 
levels of the commonly used biomarker, 25-hydroxyvitamin D, and molecular effects in 
humans in vivo.  We have demonstrated here, for the first time, differential gene 
expression in lung associated with the physiologic range of 25-hydroxyvitamin D in a 
diverse sample of free-living humans.  The candidate genes considered had prior 
evidence of modulation by 1,25-dihydroxyvitamin D in cell culture and/or animal models, 
and the subset of genes with statistically significant differences in expression by serum 
25-hydroxyvitamin D levels have known roles in biological processes relevant to lung 
health.  These results suggest mechanisms for the role of vitamin D in cancer, asthma, 
COPD, and response to infection, and we have identified a physiological range for 25-
hydroxyvitamin D at which differential responses occur at the molecular level.  The 
results inform future discussions of public health recommendations for optimal serum 
25-hydroxyvitamin D levels, and will help to guide the design of randomized controlled 
intervention trials for vitamin D in lung disorders.  
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Table 4.1. Characteristics of 26 Non-smoking Human Volunteers by Tertile of Serum 
Vitamin D.  
 
*mean (standard deviation), unless otherwise noted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Serum Vitamin D 
Variable Tertile 1  (n=9) Tertile 2  (n=9) Tertile 3 (n=8) 
Serum 25-OH-D, ng/mL  
(range) 
 
8.99 (2.3 - 11.8) 20.9 (12.7 - 26.7) 33.3 (27.9 - 39.7) 
Age, years (median)  36.9 (38) 44.1 (45) 
 
50.6 (46.5) 
 
Males (%) 6 (67%) 6 (67%) 7 (87%) 
 
Race/Ethnicity (%) 
 
African American 
 
 
 
5 (56%) 
 
 
 
6 (67%) 
 
 
 
1 (13%) 
 
European 
 
1 (11%) 
 
3 (33%) 
 
7 (87%) 
 
Hispanic 
 
Asian 
 
2 (22%) 
 
1 (11%) 
 
0 (0%) 
 
0 (0%) 
 
0 (0%) 
 
0 (0%) 
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Table 4.2.  Fold Change in Expression and P-value of Nominally Significant (p<0.05) 
Candidate Genes. 
Abbreviation: CHR, chromosome 
*Fold change in high versus low tertile serum 25-hydroxyvitamin D 
**FDR adjusted p-value (Calculated with QVALUE software by Alan Dabney and John 
Storey.  http://genomics.princeton.edu/storeylab/qvalue/index.html) 
 
 
Gene Gene name CHR Fold 
Change* 
P-value Q-value** 
KCNS3 Potassium voltage-
gated channel, 
delayed-rectifier, 
subfamily S, member 
3 
 
2 -1.62 0.00084 0.12739 
FSTL1 Follistatin-like 1 3 -1.55 0.00163 0.12739 
DAPK1 Death-associated 
protein kinase 1 
9 -2.06 0.00381 0.19820 
RSAD2 Radical S-adenosyl 
methionine domain 
containing 2 
2 1.41 0.01103 0.43023 
CST6 Cystatin E/M 11 1.79 0.01516 0.47285 
KAL1 Kallmann syndrome 1 
sequence 
X -1.38 0.01840 0.47828 
SLITRK6 SLIT and NTRK-like 
family, member 6 
13 -1.52 0.02482 0.49106 
TMEM40 Transmembrane 
protein 40 
3 1.55 0.02518 0.49106 
EMB Embigin 5 1.52 0.03099 0.50707 
PTGER2 Prostaglandin E 
receptor 2 (subtype 
EP2) 
14 1.36 0.03574 0.50707 
DTX4 Deltex homolog 4 11 -1.34 0.03812 0.50707 
KLF4 Kruppel-like factor 4 9 1.66 0.03901 0.50707 
SGPP2 Sphingosine-1-
phosphate 
phosphatase 2 
2 1.69 0.04491 0.53897 
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Table 4.3. Linear Regression of Nominally Significant (p<0.05) Candidate Genes, 
Predicting Gene Expression by Serum Vitamin D Concentration (linear variable, 
including full range of vitamin D) 
 
Gene Gene Name Regression 
Coefficient Beta (SE) 
R-squared (%)* 
KCNS3 Potassium voltage-
gated channel, 
delayed-rectifier, 
subfamily S, member 3 
 
-0.247 28% 
FSTL1 Follistatin-like 1 -21.1 40% 
DAPK1 Death-associated 
protein kinase 1 
-0.768 17% 
RSAD2 Radical S-adenosyl 
methionine domain 
containing 2 
1.99 16% 
CST6 Cystatin E/M 2.95 20% 
KAL1 Kallmann syndrome 1 
sequence 
-9.20 28% 
SLITRK6 SLIT and NTRK-like 
family, member 6 
-11.3 25% 
TMEM40 Transmembrane 
protein 40 
0.448 23% 
EMB Embigin 0.482 23% 
PTGER2 Prostaglandin E 
receptor 2 (subtype 
EP2) 
2.32 9% 
DTX4 Deltex homolog 4 -12.0 15% 
KLF4 Kruppel-like factor 4 1.71 9% 
SGPP2 Sphingosine-1-
phosphate 
phosphatase 2 
1.09 24% 
*R-squared is the proportion of the variance in expression accounted for by serum 
vitamin D 
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Table 4.4. Gene Ontology of Nominally Significant Candidate Genes from the 
UniProtKb-GOA Database (http://www.ebi.ac.uk/QuickGO/) 
 
Gene Gene Name Function(s) Pathway(s) Location(s) 
KCNS3  
 
 
Potassium voltage-
gated channel, 
delayed-rectifier, 
subfamily S, member 
3 
 
delayed-rectifier 
potassium channel 
potassium ion 
transport, 
regulation of insulin 
secretion 
Golgi and 
plasma 
membrane 
FSTL1 
 
 
Follistatin-like 1 calcium ion binding, 
heparin binding 
Bone 
morphogenetic 
protein signaling 
pathway 
Extracellular 
space 
DAPK1 
 
 
Death-associated 
protein kinase 1 
ATP and calmodulin 
binding 
intracellular protein 
kinase cascade, 
apoptosis 
regulation 
actin 
cytoskeleton 
RSAD2 
 
 
Radical S-adenosyl 
methionine domain 
containing 2 
 iron-sulfur cluster 
binding, metal ion 
binding 
defense response 
to virus 
endoplasmic 
reticulum 
CST6  Cystatin E/M cysteine-type 
endopeptidase 
inhibitor 
anatomical 
structure 
morphogenesis 
cornified 
envelope, 
extracellular 
region 
KAL1 Kallmann syndrome 
1 sequence 
extracellular matrix 
structural 
component, serine-
type endopeptidase 
inhibitor 
axon guidance, 
chemotaxis, cell 
movement, cell 
adhesion 
cell surface, 
extracellular 
space 
SLITRK6 
 
SLIT and NTRK-like 
family, member 6 
N/A axonogenesis integral 
membrane 
protein 
TMEM40 
 
 
Transmembrane 
protein 40 
N/A N/A integral 
membrane 
protein 
EMB 
 
Embigin N/A cell adhesion integral 
membrane 
protein 
PTGER2 
 
Prostaglandin E 
receptor 2 (subtype 
EP2) 
G protein coupled 
receptor for 
prostaglandin E  
GPCR signaling, 
regulation of cell 
proliferation 
integral to 
plasma 
membrane 
DTX4 
 
Deltex homolog 4 zinc ion binding Notch signaling 
pathway 
cytoplasm 
KLF4 
 
Kruppel-like factor 4 transcription 
repressor activity 
regulation of cell 
proliferation, 
mesodermal cell 
fate determination 
nuclear 
SGPP2 
 
Sphingosine-1-
phosphate 
phosphatase 2 
sphingosine-1-
phosphate 
phosphatase activity 
sphingosine 
metabolic process 
endoplasmic 
reticulum 
membrane 
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Supplemental Table 4.1. List of 156 Candidate Genes Examined for Differential Gene 
Expression 
 
ACAD8 EIF2C2 KMO SCPEP1 
ADAM28 ELP4 KRAS SDC1 
ADRB2 EMB LAMB3 SEMA4B 
AKR1C1 ENTPD3 LGALS8 SERPINB13 
ALMS1 ETNK2 LOC113230 SERPINB3 
ALOX5 EVI5 LOC157381 SGPP2 
ALS2 FAM38A LOC284837 SIX2 
ANTXR2 FAM45B LYN SLC30A1 
ARL2BP FAM49A MAFB SLITRK6 
C14orf149 FGFBP1 MAFF SMAD7 
CA2 FHOD3 MAN1C1 SNCAIP 
CAB39 FLRT3 MAN2C1 SOX9 
CASP4 FOXF1 MAP3K8 SP100 
CD14 FOXQ1 MMP1 SQLE 
CD86 FSTL1 MPHOSPH6 ST3GAL6 
CFL2 GADD45A MYO1D ST8SIA1 
CHIC2 GALNT5 NAV3 STAMBP 
CHST11 GCH1 NFKBIZ STAU2 
CLC GCNT1 NSUN6 STK39 
CLGN GEM OASL TAF1B 
COL16A1 GIMAP8 OLR1 TCF7L1 
COL1A1 GREM1 OSTalpha TM4SF1 
COLEC12 HBEGF OXTR TM7SF3 
CST6 HSD17B2 PAK6 TMEM27 
CTSD IER3 PAX9 TMEM40 
CXCL11 IFIT1 PCYOX1 TNFRSF19 
DAPK1 IFIT2 PDE4B TPBG 
DCN IGFBP3 PINK1 TPST1 
DNAJC3 INHBA PODXL TRAF4 
DNER ITPKB PRICKLE2 TRIM23 
DOCK11 JAG2 PTGER2 ULK1 
DOCK4 JUNB PTPRM USP40 
DTX4 KAL1 PTPRZ1 UST 
DUSP5 KCNJ15 RAB3IP VGLL4 
EAF2 KCNS3 RASEF WNT5A 
EFNB2 KIAA1967 RP2 WSB1 
EGR3 KIF3A RRAD YPEL3 
EHBP1L1 KLF4 RSAD2 ZNF165 
EHD4 KLK13 S100A8 ZNF318 
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CHAPTER 5 
CONCLUSION AND FUTURE DIRECTIONS 
 
The studies presented in this dissertation have examined the role of vitamin D in lung 
health using complementary epidemiologic, genetic, and functional genomics 
approaches.  Taken together, the majority of the evidence suggests that vitamin D is 
important in healthy lung function, and that the mechanism of action involves regulation 
of gene expression in processes of inflammation and immunomodulation, cell 
proliferation and cell fate determination. 
 
The first study (Chapter 2) investigated the association of serum 25-hydroxyvitamin D 
with lung function (FEV1 and FEV1/FVC) in Health ABC study participants.  The cross-
sectional association of serum 25-hydroxyvitamin D with FEV1 was positive and 
statistically significant and the effect size was of interest.  Counting the study presented 
in this dissertation, there are now two cross-sectional results showing a positive 
association of 25-hydroxyvitamin D with FEV1 [1], and one cross-sectional study 
reporting no association [2].  We extended the cross-sectional result to examine the 
longitudinal association of serum 25-hydroxyvitamin D with FEV1 over the ten year 
follow-up period.  Individuals in the lowest tertile of serum vitamin D at the start of the 
study were more likely to die or miss clinic visits over the subsequent period, leading to 
selective loss of lung function measurements in this group.  To avoid selection bias, the 
longitudinal analysis was limited to the upper two tertiles of serum 25-hydroxyvitamin D 
(20.6 ng/mL - 75 ng/mL), and there was little or no association between vitamin D 
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concentration and FEV1 decline.  These results suggest that there is no benefit to 
supplementation of elderly patients with serum 25-hydroxyvitamin D at 20 ng/mL or 
above.  However, if the vitamin D-lung function association in the cross sectional 
analysis is indeed causal, then one possibility is that vitamin D led to a change in 
decline in lung function during an earlier stage of life.  If this is the case, then future 
longitudinal studies in younger populations may detect an association of vitamin D 
nutriture with rate of decline in FEV1.  It should be noted that, by themselves, these 
results do not rule out the possibility of reverse causation as an alternative explanation 
for the cross-sectional association. 
 
The second study (Chapter 3) examined genetic associations that are theoretically free 
from the lifestyle confounding that is problematic in associations with serum 25-
hydroxyvitamin D.  In African-American participants in the Health ABC study, a SNP and 
two haplotypes in CYP24A1 were associated with FEV1, and a SNP in VDR was 
associated with FEV1/FVC after correction for multiple testing.  In European-Americans, 
two interactions between SNPs in RXRA and serum 25-hydroxyvitamin D were 
significant at a false discovery rate < 0.2.  These results, which characterize vitamin D 
nutriture via genetic proxies, strongly support a causal role of vitamin D in lung health, 
since function of these genes is critical for vitamin D activity at the cellular level.  
Individuals with variants in CYP24A1 may have altered half-life and/or levels of 1,25-
dihydroxyvitamin D, since this gene encodes the enzyme responsible for degrading the 
active form of vitamin D.  A genetic variant altering VDR function would affect the ability 
of vitamin D to modulate gene expression, given VDR binding in the cytoplasm is the 
first step to nuclear localization of the complex for gene regulation.  Similarly, RXRA is 
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crucial for transcriptional regulation by vitamin D; compromised lung function was 
observed for the combination of low serum 25-hydroxyvitamin D with SNPs in RXRA, 
and with little or no association of the RXRA SNPs at high serum 25-hydroxyvitamin D 
levels.  These results strongly suggest that the mechanism of action for these RXRA 
genetic variants is through the participation of RXRA in the vitamin D/VDR heterodimer 
rather than through another heterodimeric pairing in a different pathway.  All three 
genes with statistically significant associations with pulmonary phenotypes (CYP24A1, 
VDR, and RXRA) function downstream of 25-hydroxyvitamin D, and the genetic variants 
did not have a detectable effect on circulating 25-hydroxyvitamin D concentration.  
Thus, this study provides evidence complementary to the epidemiologic study of serum 
25-hydroxyvitamin D in the Health ABC population.  The association of genetic variants 
in vitamin D metabolic genes with pulmonary phenotypes are hypothesized to represent 
the cumulative effect of a lifetime of altered vitamin D net functionality, confirming the 
importance of vitamin D in lung health.  Of note, the issue of timing of vitamin D effects 
is not addressed by the genetic study, as there is no way to deduce from these results 
whether there is a critical time period for vitamin D nutriture.  As with any genetic study, 
it is possible that the most important time period for vitamin D functionality is during lung 
development and growth, in the prenatal period or during infancy.  However, the current 
epidemiological evidence, from the NHANES III [1] study and from the results reported 
herein, supports the inference that adult vitamin D levels are important for maintaining 
lung function.   
 
The third study (Chapter 4) addresses the question of mechanisms in a study of lung 
tissue gene expression. In this study, we sought to understand how gene expression 
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modulated by vitamin D affects lung health by studying the association of serum levels 
of 25-hydroxyvitamin D with altered function at the molecular level.   We found 
differential gene expression in lung epithelial cells associated with the physiological 
range of 25-hydroxyvitamin D in a diverse sample of free-living humans.  In this 
hypothesis-driven study, candidate genes were selected for study only if there was 
evidence of in vitro regulation by vitamin D and if the gene contained a vitamin D 
response element.Thirteen genes had statistically significant changes in expression 
between low and high serum concentrations of 25-hydroxyvitamin D, and 3 genes were 
significant at FDR < 0.2. Gene ontology and literature analysis of differentially 
expressed genes supported plausible mechanisms for functional roles in asthma, 
COPD, cancer, and response to infection in lung.  Many genes were known to function 
in cell proliferation or cell fate determination, which could affect cancer development 
and progression, as well as processes of airway remodeling in COPD and asthma.  
Several genes also had well-established immunomodulatory effects, with known roles 
either in inflammation (relevant to obstructive lung disease), or response to pathogens 
(relevant to respiratory infections).  In addition, striking similarities between 
glucocorticoid responses and vitamin D-associated gene expression were observed, 
suggesting that combination therapies of vitamin D and glucocorticoids may have 
synergy by producing similar effects through different pathways. 
 
Our results also provide information that may be useful for any future intervention trials 
studying the use of vitamin D supplementation to maintain lung health.  Specifically, 
changes in the expression of the panel of genes identified here could be used to identify 
effects of varying doses of dietary vitamin D.  Ultimately, monitoring concentrations of 
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serum 25-hydroxyvitamin D corresponding with changes in expression of these genes 
may help to establish optimal levels of serum vitamin D for lung outcomes. 
 
It should be noted that there are some limitations inherent to the studies described here.  
The epidemiologic study cannot rule out the possibilities of reverse causation or lifestyle 
confounding producing the cross-sectional result, although every effort was made to 
adjust for potential confounders.  The study of genetic associations provides stronger 
evidence for a role for vitamin D in lung health, but false positives are possible.  In 
addition, variants in RXRA may affect some other pathway involving a heterodimeric 
partner other than VDR; however, this is unlikely given that interactions with 25-
hydroxyvitamin D level were detected for RXRA.  Similarly, false positives are possible 
in the expression microarray results, although limiting hits to FDR < 0.2 and genes with 
predicted VDRE‘s and prior evidence of vitamin D modulation decreases the likelihood 
of spurious associations.  Perhaps a more difficult problem to address fully is whether 
the changes in expression are physiologically relevant, because it is unclear what 
degree of fold change is required to affect cell function, and this quantity may vary for 
each gene.   
 
Future studies may strengthen evidence for a role for vitamin D in lung health by 
building on these results.  Additional longitudinal association studies are needed in 
younger populations to determine at which life stages vitamin D nutriture is most 
important for lung function.  In vitro experimentation in cells carrying the genetic variants 
associated with lung function (for example, lymphoblasts from International HapMap 
project participants) could be used to verify that these genotypes respond differently to 
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1,25-dihydroxyvitamin D treatment.  For example, effects of RXRA or VDR SNPs on 
gene expression changes for a representative panel of vitamin D target genes could be 
evaluated, as well as duration of response for CYP24A1 variants.  Interestingly, in vitro 
follow-up for the microarray study has essentially already been done by prior studies.  
Instead, a small proof-of-concept study verifying that vitamin D supplementation alters 
expression of these genes in lung, with comparison to effects on these genes in a more 
accessible tissue such as blood cells, would be a helpful first step towards a full-scale 
randomized controlled trial of vitamin D for COPD.  Ideally, experimentation with 
multiple doses could be used to establish a dose-response relationship between dietary 
vitamin D, resulting 25-hydroxyvitamin D levels, and molecular changes in lung.   
 
In summary, this dissertation describes the findings of several studies aimed at 
understanding the role of vitamin D in lung health. We found a cross-sectional 
association of the serum biomarker of vitamin D with lung function, and genetic variants 
in genes in the vitamin D metabolic pathway were also associated with lung function.  
By using complementary approaches, we were able to address the issue of confounding 
that makes causal inferences especially challenging in vitamin D research. Furthermore, 
in a study of lung epithelial cells we demonstrated molecular effects associated with 
concentrations of the serum biomarker of vitamin D, which is a first step to establishing 
dose-response relationships.  Overall, the findings support an important role for vitamin 
D in maintaining lung health, and vitamin D-regulated gene expression may have a 
plausible role in processes related to COPD, asthma, cancer, and respiratory infections.   
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